

CHD AUC Final Ratings

Table 1: Patent Foramen Ovale (PFO), Atrial Septal Defects (ASD), and Partial Anomalous Pulmonary Venous Connection (PAPVC)

		Panelist 1	Panelist 2	Panelist 3	Panelist 4	Panelist 5	Panelist 6	Panelist 7	Panelist 8	Panelist 9	Panelist 10	Panelist 11	Panelist 12	Panelist 13	Panelist 14	Panelist 15	Panelist 16	Panelist 17	MEDIAN SCORE	AUC RATING		
Patent Foramen Ovale	1. Routine surveillance of an asymptomatic patient with a PFO	TTE	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	4	3	1	R	
		TTE + Contrast	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	2	1	R
		TEE	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	1	R
Atrial Septal Defects: Unrepaired	2. Routine surveillance (1-2 years) in an asymptomatic patient with a small ASD or PAPVC involving a single pulmonary vein	TTE	4	4	4	1	4	4	5	4	2	4	5	4	5	5	4	7	5	4	M	
		TTE	7	7	7	7	7	8	7	7	5	7	7	9	9	7	7	9	7	7	A	
	3. Routine surveillance (3-5 years) in an asymptomatic patient with a small ASD or PAPVC involving a single pulmonary vein	TTE	7	7	7	7	7	8	7	7	5	7	7	9	9	7	7	9	7	7	A	
		TTE	7	8	8	8	8	8	8	8	7	8	7	9	8	7	3	9	7	8	A	
	4. Routine surveillance (1-2 years) in an asymptomatic patient with ≥ moderate ASD or PAPVC involving more than one pulmonary vein	CMR	4	4	4	5	6	4	6	4	1	4	4	4	4	4	4	3	5	4	M	
		CCT	4	4	4	5	5	4	4	4	1	4	4	4	4	4	4	3	4	4	M	
	5. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TTE + Contrast	5	5	5	4	5	5	4	4	6	4	8	5	5	5	5	6	6	5	M	
		TEE	5	6	6	6	6	6	4	5	7	5	5	5	5	5	5	6	7	5	M	
		CMR	6	6	6	6	6	6	5	6	7	6	5	6	5	5	5	6	8	6	M	
		CCT	3	3	3	4	2	3	5	3	7	3	4	5	2	3	3	6	8	3	R	
	6. Evaluation to determine the method of closure of isolated secundum ASD	TTE	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	A	
		TTE + Contrast	4	4	4	5	4	3	3	4	4	3	4	4	5	4	4	4	5	4	M	
		TEE	7	7	7	9	7	8	9	7	9	8	9	7	9	7	7	7	8	7	A	
CMR		5	4	5	7	5	5	5	6	3	5	6	5	4	5	5	6	8	5	M		
CCT		3	3	3	7	3	2	5	3	3	3	5	3	2	3	3	4	8	3	R		
7. Evaluation prior to planned repair of sinus venosus defeCCT and/or PAPVC	TTE	9	9	9	9	9	9	9	9	9	5	9	9	9	9	9	9	9	9	A		
	TTE + Contrast	4	4	4	6	4	4	4	4	4	3	4	4	5	4	4	4	9	4	M		
	TEE	7	7	7	8	7	7	7	7	9	7	7	7	9	7	7	7	7	7	A		
	CMR	7	8	8	8	9	8	7	8	9	8	8	8	9	8	8	8	9	8	A		
	CCT	7	7	7	7	8	7	7	7	9	8	8	8	8	9	7	6	7	9	7	A	
Atrial Septal Defects: Post-procedural: Surgical or Catheter-based	8. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		

9. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE + Contrast	5	5	5	1	5	5	5	5	7	4	5	5	5	5	7	9	5	M	
	CMR	1	2	2	1	1	2	1	2	1	2	2	2	1	2	2	4	6	2	R
	CCT	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	4	6	1	R
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TTE + Contrast	5	6	6	8	5	6	5	5	9	6	6	5	4	5	5	8	9	6	M
	TEE	8	7	7	7	8	8	9	8	9	8	8	7	8	7	7	8	9	8	A
10. Routine surveillance within 1 week following device closure of ASD in an asymptomatic patient with no or mild sequelae	CMR	7	7	7	7	7	7	8	7	9	6	6	7	8	7	7	9	7	A	
	CCT	7	7	7	7	7	7	8	7	9	6	6	7	8	7	6	5	9	7	A
	TTE	9	8	8	9	8	8	8	8	9	9	9	9	9	9	8	9	8	9	A
	TTE + Contrast	3	3	3	8	3	2	5	3	6	3	1	3	3	3	3	4	7	3	R
	TTE	9	9	9	9	8	9	8	9	9	9	9	9	9	9	7	9	8	9	A
	TTE + Contrast	6	3	3	9	3	2	5	3	5	3	2	3	3	3	3	5	6	3	R
11. Routine surveillance at 1 month following device closure of ASD in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	8	9	8	9	9	9	9	9	9	9	7	9	8	9	A
	TTE + Contrast	6	3	3	9	3	2	5	3	5	3	2	3	3	3	3	5	6	3	R
12. Routine surveillance at 3-6 months following device closure of ASD in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	8	9	9	8	9	6	9	9	9	9	9	8	9	8	9	A
	TTE + Contrast	1	3	3	7	3	2	5	3	1	3	2	3	3	3	3	4	6	3	R
13. Routine surveillance at 1 year following device closure of ASD in an asymptomatic patient with no or mild sequelae	TTE	9	8	8	9	9	8	8	9	6	9	9	9	9	7	8	9	8	9	A
	TTE + Contrast	3	3	2	7	2	2	5	3	1	3	2	2	3	2	2	7	6	3	R
14. Routine surveillance (2-5 years) after the first year following device closure of ASD in an asymptomatic patient with no or mild sequelae	TTE	9	8	8	9	8	8	8	8	9	9	9	9	9	7	8	9	8	8	A
	TTE + Contrast	1	2	2	7	2	2	5	2	6	3	2	2	3	2	2	4	6	2	R
15. Routine surveillance within a year following surgical ASD closure or PAPVC repair in an asymptomatic patient with no or mild sequelae	TTE	9	8	8	9	8	9	8	8	9	7	9	9	9	9	8	9	6	9	A
	TTE + Contrast	2	2	2	7	2	2	5	2	4	4	1	2	3	3	2	7	6	2	R
16. Routine surveillance (annually) after the first year following surgical ASD closure or PAPVC repair in an asymptomatic patient with no or mild sequelae	TTE	8	5	6	9	9	5	6	7	9	6	5	4	9	6	4	6	5	6	M
	TTE + Contrast	2	2	2	7	2	2	2	2	3	3	2	1	3	2	2	3	5	2	R
	CMR	7	2	3	2	7	2	3	3	1	3	1	1	3	3	2	2	5	3	R
	CCT	5	2	2	2	7	2	3	2	1	4	1	1	3	3	2	2	3	2	R

17. Routine surveillance (2-5 years) after the first year following surgical ASD closure or PAPVC repair in an asymptomatic patient with no or mild sequelae	TTE	8	9	9	9	8	9	8	9	9	9	8	9	9	9	8	9	7	9	A
	TTE + Contrast	2	2	2	7	2	2	5	2	6	3	2	2	3	2	2	4	4	2	R
	CMR	3	5	5	5	2	4	3	5	4	4	2	5	3	4	4	4	7	4	M
	CCT	1	4	4	5	2	4	3	4	4	4	2	4	3	4	4	4	4	4	M
18. Routine surveillance (3 to 12 months) following surgical or device closure of ASD in a patient with significant residual shunt, valvular or ventricular dysfunction, arrhythmias, and/or pulmonary hypertension	TTE	6	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TTE + Contrast	2	4	4	7	4	4	4	4	9	4	6	5	6	5	4	7	5	4	M
	TEE	3	5	5	4	5	5	4	5	9	5	4	3	6	5	5	7	7	5	M
	CMR	4	5	5	5	6	5	6	5	4	5	4	5	6	5	5	4	9	5	M
	CCT	3	4	4	5	4	4	6	4	4	4	4	5	6	4	4	3	7	4	M
19. Routine surveillance (3 to 12 months) following repair of PAPVC in a patient with systemic or pulmonary venous obstruction, valvular or ventricular dysfunction, arrhythmias, and/or pulmonary hypertension	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TTE + Contrast	2	5	5	7	5	5	4	5	9	6	4	5	6	5	5	7	5	5	M
	TEE	2	5	5	4	6	5	4	5	9	5	5	4	6	5	5	7	6	5	M
	CMR	4	5	5	5	5	5	6	5	4	5	5	5	6	5	5	6	9	5	M
	CCT	5	4	4	5	4	5	6	4	4	4	5	5	6	5	4	5	7	5	M

Table 2: Ventricular Septal Defects (VSD)

Unrepaired	20. Routine surveillance (annually) in an asymptomatic child with a small muscular VSD	TTE	3	2	4	2	3	2	3	3	3	3	3	3	2	3	7	3	3	R	
	21. Routine surveillance (2-5 years) in an asymptomatic child with a small muscular VSD	TTE	7	7	7	9	7	7	7	7	3	7	5	7	9	7	7	9	5	7	A
	22. Routine surveillance (2-5 years) in an asymptomatic adult with a small muscular VSD	TTE	7	7	7	9	7	6	7	7	5	7	4	7	9	7	7	7	7	7	A
	23. Routine surveillance (1-2 years) in an asymptomatic patient with a small VSD in a location other than muscular septum	TTE	7	8	8	7	7	8	7	8	4	7	8	7	9	7	7	9	6	7	A
	24. Routine surveillance (3-5 year(s)) in an asymptomatic adult with a small VSD in a location other than muscular septum	TTE	7	8	8	9	8	8	9	8	4	8	8	8	9	7	8	9	6	8	A
		TEE	1	4	4	5	4	4	3	5	3	4	4	4	6	5	4	6	3	4	M

	CMR	3	3	8	3	3	5	3	5	3	3	3	3	6	3	3	3	6	3	R
25. Routine surveillance (1-3 months) in an infant with ≥ moderate VSD on medical management	TTE	9	9	8	9	8	9	9	8	9	8	9	9	9	8	8	9	7	9	A
26. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	4	6	6	5	6	6	5	6	6	6	7	6	6	5	6	8	7	6	M
	CMR	5	6	6	5	6	6	8	6	7	5	6	6	6	5	5	7	9	6	M
	CCT	5	4	4	5	4	4	8	4	7	4	6	4	4	4	4	7	8	4	M
27. Evaluation prior to planned repair	TTE	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	1	6	6	5	6	6	7	6	9	6	7	6	6	5	6	8	7	6	M
	CMR	1	6	6	5	6	6	6	6	7	5	7	6	6	5	6	7	9	6	M
	CCT	1	3	4	5	3	2	6	3	7	3	6	4	4	4	3	7	7	4	M
Post-procedural: Surgical or Catheter-based	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
28. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
29. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	6	6	6	8	7	7	9	7	6	7	6	6	6	6	6	8	9	6	M
	CMR	6	6	6	8	6	6	9	6	6	5	6	6	6	6	6	7	9	6	M
	CCT	4	5	6	8	6	6	9	6	6	6	5	6	6	6	5	7	9	6	M
30. Routine surveillance within a year following surgical or device VSD closure in an asymptomatic patient with no or mild sequelae	TTE	9	8	8	9	9	8	9	8	7	8	7	8	9	7	8	9	5	8	A
31. Routine surveillance (2-3 years) after the first year following device closure of VSD in an asymptomatic patient with no or mild sequelae	TTE	9	8	7	9	9	8	9	8	7	9	8	8	9	9	9	9	9	9	A
32. Routine surveillance (annually) after the first year following surgical VSD closure in an asymptomatic patient with no or mild sequelae	TTE	9	5	4	2	8	2	5	4	6	3	5	4	6	4	4	6	6	5	M
33. Routine surveillance (2-3 years) after the first year following surgical VSD closure in an asymptomatic patient with no or mild sequelae	TTE	9	8	8	9	8	8	9	8	7	8	9	8	9	7	7	7	8	8	A

34. Routine surveillance (2-3 years) following surgical or device closure in a patient with small residual shunt, ≤ mild valvular dysfunction, no ventricular dysfunction, arrhythmias or pulmonary hypertension	TTE	9	9	9	9	9	9	9	9	9	8	8	9	9	9	8	9	9	9	A
	TEE	2	2	3	3	6	2	6	3	3	3	3	1	4	3	9	3	4	3	R
	CMR	3	2	4	3	3	2	3	3	2	3	3	1	4	3	5	4	4	3	R
	CCT	1	2	4	1	3	2	1	3	2	3	3	1	4	3	5	3	4	3	R
35. Routine surveillance (3 to 12 months) following surgical or device closure in a patient with significant residual shunt, valvular or ventricular dysfunction, arrhythmias, and/or pulmonary hypertension	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	1	5	5	8	5	5	5	5	6	5	6	4	6	5	5	7	6	5	M
	CMR	1	5	5	8	5	5	5	5	3	5	6	6	6	5	5	5	7	5	M
	CCT	1	4	4	8	4	4	5	4	3	4	6	4	6	5	4	5	6	4	M

Table 3: Atrioventricular Septal Defects (AVSD)

Unrepaired: Partial/Conditional	36. Routine surveillance (3-6 months) in an asymptomatic infant	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A	
	37. Routine surveillance (1-2 years) in an asymptomatic child	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
Unrepaired: Complete	38. Routine surveillance (1-3 months) in an infant	TTE	9	9	9	5	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
Unrepaired: All Types	39. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	5	5	5	7	6	6	6	5	6	4	6	5	6	5	5	7	9	6	M
		CMR	5	5	5	7	5	5	7	5	7	4	5	5	6	5	5	6	9	5	M
		CCT	4	4	4	7	4	4	7	4	3	3	5	4	4	5	4	6	9	4	M
	40. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	5	5	5	8	5	5	6	5	9	4	6	5	6	5	5	7	9	5	M
		CMR	5	5	5	6	5	5	5	5	9	4	5	5	6	5	5	4	9	5	M
		CCT	4	4	4	6	4	4	5	4	9	4	5	4	6	5	4	4	9	4	M
Post-operative	41. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	42. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	6	6	6	7	7	6	6	6	9	6	6	6	6	6	6	7	8	6	M
		CMR	6	6	6	6	6	6	6	6	6	6	5	6	6	6	5	7	9	6	M
		CCT	5	5	5	6	5	5	6	5	6	5	5	6	6	5	4	6	8	5	M

43. Routine surveillance within a year after AVSD repair in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	7	9	A
44. Routine surveillance (1-3 year(s)) after the first year following repair in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	7	9	9	9	8	9	9	9	9	9	9	9	9	9	9	A
45. Routine surveillance (3-12 months) in a patient with significant residual shunt, valvular or ventricular dysfunction, LVOT obstruction, arrhythmias, and/or pulmonary hypertension	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	6	5	5	7	7	5	4	6	6	5	6	5	6	5	5	7	6	6	M
	CMR	6	5	6	7	6	6	5	7	6	6	4	6	6	6	5	7	9	6	M
	CCT	6	3	4	7	3	3	5	5	6	3	4	3	6	3	4	6	8	4	M
46. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	6	5	6	5	8	6	3	5	5	6	5	5	6	6	5	7	9	6	M
	CCT	6	3	4	5	6	3	3	3	3	3	4	3	6	5	4	6	8	4	M

Table 4: Patent Ductus Arteriosus (PDA)

Unrepaired	47. Routine surveillance (3-5 years) in an asymptomatic patient with a trivial, silent PDA	TTE	3	3	3	9	5	1	5	3	9	2	2	3	9	2	3	7	4	3	R
	48. Routine surveillance (3-6 months) in an infant with ≥ moderate PDA	TTE	7	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	A
		CMR	1	2	3	1	2	2	3	2	3	3	3	2	3	3	1	1	6	2	R
		CCT	1	2	3	1	1	1	3	2	3	3	2	2	3	3	1	1	5	2	R
	49. Routine surveillance (3-6 months) in an infant or child with a small, audible PDA until closure	TTE	9	6	7	9	9	5	9	7	9	9	8	3	6	7	3	9	7	7	A
	50. Routine surveillance (1-2 years) in an infant or child with a small, audible PDA until closure	TTE	9	8	8	9	8	9	9	9	9	7	8	7	9	7	7	9	7	8	A
		TTE	9	9	9	9	8	6	9	8	9	2	8	9	9	8	3	9	6	9	A
	51. Routine surveillance (3-5 years) in an adult with a small PDA	CMR	1	2	4	2	3	2	3	2	2	2	3	3	3	3	1	4	4	3	R
		CCT	1	2	4	1	3	2	3	2	2	2	3	2	3	3	1	3	4	2	R
		TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	9	9	A
	52. Evaluation due to change in clinical status and/or new concerning signs or symptoms	CMR	3	6	6	7	7	6	6	6	6	6	5	6	6	5	6	7	9	6	M
		CCT	1	5	5	7	6	5	6	5	6	5	4	5	3	6	4	7	9	5	M

	53. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	1	4	5	7	7	4	6	5	6	4	6	4	6	2	5	7	9	5	M
		CCT	1	4	5	7	6	5	6	5	6	5	5	5	6	5	4	7	9	5	M
Post-procedural: Surgery or Catheter-based	54. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE																			
	55. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	1	4	4	7	5	4	3	4	6	4	3	4	5	5	4	7	7	4	M
		CMR	5	5	5	7	6	5	8	5	6	5	5	5	5	5	4	7	9	5	M
		CCT	5	5	5	7	5	5	8	5	6	5	4	5	5	5	4	6	9	5	M
		Lung Scan	5	4	4	7	4	4	5	4	7	4	4	4	5	5	4	6	6	4	M
	56. Routine surveillance (annually) within 2 years following PDA closure in an asymptomatic patient with no or mild sequelae	TTE	5	9	7	5	8	8	9	7	9	8	8	8	7	9	5	5	5	8	A
		TTE	4	3	4	1	3	3	9	3	9	3	3	3	9	3	4	8	6	3	R
	58. Routine surveillance (5 years) after the first 2 years following device closure in an asymptomatic patient with no or mild sequelae	TTE	8	7	4	9	3	5	9	7	6	6	7	7	9	7	3	8	6	7	A
TTE		9	9	9	9	9	9	9	9	9	9	7	9	9	9	9	8	8	9	A	
59. Routine surveillance (1-2 years) in a patient with post-procedural left pulmonary artery stenosis	CMR	6	6	6	7	6	6	7	7	7	6	6	6	9	6	6	6	8	6	M	
	CCT	5	6	6	7	6	6	7	6	6	6	6	6	9	6	5	6	8	6	M	
	Lung Scan	5	7	7	9	7	8	7	3	7	7	7	7	9	7	7	7	6	7	A	
60. Routine surveillance (1-2 years) in a patient with post-procedural aortic obstruction	TTE	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	A	
	CMR	6	7	7	7	8	7	7	7	7	6	7	7	9	7	7	6	9	7	A	
	CCT	6	6	6	7	7	6	7	6	7	6	7	7	9	7	5	6	8	7	A	
Table 5: Total Anomalous Pulmonary Venous Connection (TAPVC)																					
Unrepaired	61. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	6	6	6	7	6	4	5	6	9	5	6	6	7	6	6	7	8	6	M
		CMR	7	7	7	7	8	8	7	7	9	7	6	7	7	7	7	8	9	7	A
		CCT	6	6	7	7	6	7	7	6	9	6	6	7	7	6	6	8	8	7	A

62. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	6	6	6	8	6	3	5	6	9	6	6	6	7	6	6	7	8	8	6	M	
	CMR	7	7	7	8	8	8	8	7	9	7	7	7	7	7	7	8	9	9	7	A	
	CCT	7	7	7	8	7	8	8	7	9	7	7	7	7	7	6	8	8	8	7	A	
Post-operative	63. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	4	3	3	1	3	1	3	3	6	3	3	4	3	3	3	6	6	6	3	R
		CCT	4	3	3	1	3	1	3	3	6	3	3	4	3	3	3	6	6	6	3	R
64. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	6	7	7	7	7	7	7	6	6	7	5	5	9	7	7	7	9	9	7	A	
	CMR	6	8	8	7	8	8	7	6	7	8	7	7	8	7	8	7	9	9	7	A	
	CCT	5	8	8	7	8	8	7	5	7	8	6	7	8	7	7	6	9	9	7	A	
	Stress Imaging	1	4	3	7	2	2	3	2	3	3	6	6	3	3	3	1	9	9	3	R	
	Lung Scan	6	7	7	7	7	7	6	4	9	4	6	6	8	7	7	7	9	9	7	A	
65. Routine surveillance (3-6 months) in an asymptomatic infant with no or mild sequelae	TTE	9	8	8	9	8	8	8	8	9	8	7	9	9	8	7	9	5	5	8	A	
66. Routine surveillance (1-2 years) in an asymptomatic child with no or mild sequelae	TTE	9	9	8	9	7	8	8	8	7	8	7	9	9	9	8	9	7	7	8	A	
67. Routine surveillance (3-5 years) in an asymptomatic adult with no or mild sequelae	CMR	6	6	6	6	6	6	6	6	3	6	5	6	6	5	6	6	6	6	6	M	
	CCT	5	5	6	6	5	5	6	5	3	5	4	6	6	5	4	3	5	5	5	M	

Table 6: Eisenmenger Syndrome and Pulmonary Hypertension Associated with CHD

Eisenmenger Syndrome (ES)	68. Initial evaluation with suspicion of ES	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	7	7	7	9	7	7	6	7	6	6	8	7	9	7	7	7	8	8	7	A
		CCT	6	6	7	9	7	6	6	6	9	5	7	7	5	6	6	6	5	5	6	M
		Stress Imaging	4	4	4	9	4	4	3	4	9	3	2	4	4	4	4	6	4	4	4	M
69. Evaluation due to change in clinical status and/or new concerning signs or symptoms in a patient with ES	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	7	7	7	9	7	7	6	7	6	3	8	7	7	7	7	7	9	9	7	A	
	CCT	6	6	6	9	5	6	6	6	6	3	7	6	5	5	6	7	5	5	6	M	
	Stress Imaging	5	5	5	9	5	5	4	5	7	4	6	4	5	5	5	6	4	4	5	M	
70. Evaluation due to change in PAH-targeted therapy in a patient with ES	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	6	6	8	6	9	7	8	7	8	7	8	7	7	7	9	5	6	6	7	A	
	CCT	6	4	5	7	5	5	4	5	6	4	5	5	7	5	5	5	5	5	5	M	
	Stress Imaging	5	4	5	9	5	5	3	5	7	4	3	5	5	5	5	6	4	4	5	M	
71. Routine surveillance (3 months) in a stable child with ES	TTE	6	6	6	5	7	4	3	6	9	5	7	6	1	6	7	9	3	3	6	M	
	CMR	2	2	2	1	2	2	3	3	3	2	2	2	1	3	3	3	3	3	2	R	
	CCT	2	2	2	1	2	2	3	2	3	2	1	2	1	3	2	1	3	3	2	R	

Pulmonary Hypertension associated with CHD	72. Routine surveillance (6-12 months) in a stable child with ES	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	3	9	A
		CMR	6	3	3	5	4	3	3	3	3	2	3	3	3	3	4	5	3	3	R
		CCT	4	3	3	3	3	3	3	3	3	2	2	3	3	3	4	3	3	3	R
	73. Routine surveillance (3 months) in a stable adult with ES	TTE	4	2	3	3	3	3	1	3	3	3	2	2	3	1	5	6	4	3	R
		CMR	6	2	2	1	3	3	3	3	3	1	2	2	1	1	4	3	3	3	R
		CCT	4	2	2	1	2	3	3	2	3	1	2	2	1	1	3	1	3	2	R
	74. Routine surveillance (6-12 months) in a stable adult with ES	TTE	9	9	6	9	9	9	9	9	7	9	9	9	9	9	9	9	7	9	A
		CMR	6	3	4	6	3	4	3	3	4	3	4	3	3	3	6	4	6	4	M
		CCT	4	3	4	6	2	3	3	3	4	2	3	3	3	3	4	3	3	3	R
	75. Initial evaluation with suspicion of pulmonary hypertension following CHD surgery	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	7	7	7	9	7	7	5	7	6	6	7	7	7	7	7	7	9	7	A
		CCT	6	6	7	9	6	6	5	6	6	6	4	7	7	7	6	7	9	6	M
		Stress Imaging	6	5	5	9	5	6	3	5	6	4	3	7	5	6	5	7	5	5	M
	76. Evaluation due to change in clinical status and/or new concerning signs or symptoms in a patient with post-operative PH	TTE	9	9	9	9	9	9	9	7	9	9	9	9	9	9	7	9	9	9	A
		CMR	7	7	7	9	7	7	5	3	6	6	7	7	7	6	5	7	9	7	A
		CCT	6	6	7	9	7	6	5	2	6	6	6	7	5	6	5	7	9	6	M
		Stress Imaging	5	5	5	9	5	6	4	1	6	4	5	5	5	6	4	7	6	5	M
	77. Evaluation due to change in PAH-targeted therapy in a patient with post-operative PH	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	6	7	6	9	8	7	5	7	6	6	7	5	7	6	7	4	9	7	A
		CCT	6	5	6	9	7	6	3	6	6	4	6	5	5	6	4	3	9	6	M
		Stress Imaging	5	4	6	9	5	6	4	5	6	4	4	4	5	5	5	5	6	5	M
78. Routine surveillance (3 months) in a stable child with post-operative PH	TTE	6	7	7	3	8	7	3	7	9	6	8	7	5	7	7	9	5	7	A	
	CMR	6	3	3	3	3	3	1	3	3	2	3	3	1	3	3	3	5	3	R	
	CCT	4	2	3	3	2	2	1	2	3	2	3	2	1	3	2	1	4	2	R	
79. Routine surveillance (6-12 months) in a stable child with post-operative PH	TTE	9	9	7	9	9	9	9	8	9	9	9	9	9	9	9	9	7	9	A	
	CMR	4	3	3	5	3	2	2	3	3	3	2	2	3	3	5	7	4	3	R	
	CCT	4	3	3	5	4	3	3	3	3	2	3	2	5	4	3	3	4	3	R	
80. Routine surveillance (3 months) in a stable adult with post-operative PH	TTE	6	5	5	3	6	4	3	5	5	4	6	5	5	5	5	7	5	5	M	
	CMR	6	3	3	3	3	2	1	3	3	2	3	3	1	3	3	4	5	3	R	
	CCT	4	2	3	3	2	2	1	2	3	2	3	2	1	3	2	3	4	2	R	
81. Routine surveillance (6-12 months) in a stable adult post-operative PH	TTE	9	9	8	9	9	9	9	9	9	9	8	9	9	9	9	9	7	9	A	
	CMR	6	5	4	5	7	5	3	5	3	4	4	5	5	5	5	5	6	5	M	

		CCT	3	3	3	4	3	2	2	3	2	2	2	2	3	3	5	6	4	3	R		
Table 7: Ebstein Anomaly and Tricuspid Valve Dysplasia																							
Unrepaired	82. Routine surveillance (1-2 years) in an asymptomatic infant or child with mild TR	TTE	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	5	9	A	
		CMR	3	3	3	5	3	3	3	3	3	3	3	3	3	3	3	3	7	4	3	R	
		CCT	3	3	3	5	3	2	3	3	3	3	3	2	3	3	3	2	3	3	3	3	R
	83. Routine surveillance (3-5 years) in an asymptomatic adult with mild TR	TTE	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	A
		TTE + Contrast	4	4	4	5	5	5	4	5	6	4	4	5	3	5	4	7	5	5	5	M	
		TEE	4	4	4	7	5	4	3	4	4	4	4	4	5	5	4	5	6	4	4	M	
		CMR	5	5	5	7	7	5	3	5	4	4	7	5	5	5	5	7	9	5	5	M	
		CCT	3	3	3	7	4	3	3	3	4	3	6	4	3	3	3	4	7	3	3	R	
	84. Routine surveillance (3-6 months) in an asymptomatic infant with ≥ moderate TR without hypoxemia	TTE	9	8	8	9	9	9	9	8	9	8	9	9	9	9	9	8	9	6	9	A	
		TTE	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	7	7	9	9	A	
	85. Routine surveillance (6-12 months) in an asymptomatic patient with ≥ moderate TR and previously stable RV size and/or function without hypoxemia	TTE	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	7	7	9	A	
		TTE + Contrast	5	4	4	5	5	4	4	4	3	4	3	4	4	5	4	3	5	4	4	M	
		TEE	4	4	4	5	6	3	3	4	4	4	3	4	4	5	4	2	6	4	4	M	
		CMR	5	5	5	6	5	4	3	5	3	6	2	4	4	5	5	4	7	5	4	M	
		CCT	3	3	3	6	3	3	3	3	3	3	1	4	1	3	3	3	5	3	3	R	
	86. Evaluation due to change in clinical status and/or new concerning signs and symptoms	TTE	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	9	A	
		TTE + Contrast	9	7	7	9	4	5	6	6	9	8	7	7	4	5	6	7	9	7	7	A	
		TEE	5	7	7	9	7	5	6	7	7	7	6	7	6	5	6	7	9	7	7	A	
		CMR	5	7	7	9	7	5	7	6	9	7	6	7	7	5	6	7	9	7	7	A	
		CCT	4	6	6	9	6	4	6	5	9	5	5	6	7	5	4	5	8	6	6	M	
		Stress Imaging	3	5	6	9	5	4	7	4	6	3	3	7	5	4	4	5	8	5	5	M	
87. Evaluation of an ASD for device closure in a patient with mild or moderate TR, RV enlargement and no hypoxemia	TTE	9	9	9	9	9	9	9	9	9	7	9	9	9	9	9	9	9	9	9	A		
	TTE + Contrast	5	6	6	9	5	6	9	6	5	6	4	6	7	6	6	7	7	6	6	M		
	TEE	7	8	8	9	5	8	9	8	6	8	8	7	7	8	8	7	6	8	8	A		
	CMR	5	6	7	9	5	6	7	6	4	6	6	6	7	6	6	8	6	6	6	M		
	CCT	4	5	7	9	3	5	7	5	4	5	6	6	5	5	4	5	4	5	5	M		
88. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	A		
	TTE + Contrast	5	6	6	9	6	6	9	6	6	6	5	6	6	6	6	7	9	6	6	M		
	TEE	5	6	7	9	6	6	9	6	9	6	6	7	6	6	6	7	9	6	6	M		
	CMR	5	7	7	9	7	7	7	7	7	7	7	7	6	7	7	8	9	7	7	A		
	CCT	4	4	4	9	4	4	7	4	7	4	7	7	4	4	4	5	8	4	4	M		
	Stress Imaging	2	3	3	9	3	3	1	3	7	3	3	3	3	3	3	5	7	3	3	R		

Post-operative	89. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TTE + Contrast	6	6	6	5	7	6	6	6	4	6	4	6	6	5	6	7	9	6	M		
	90. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TTE + Contrast	7	7	7	9	7	7	9	7	6	7	6	5	6	6	7	7	9	7	A		
		TEE	7	7	7	9	7	7	6	7	6	7	7	5	7	6	7	7	9	7	A		
		CMR	6	7	7	9	7	7	6	7	6	6	7	7	6	6	6	7	9	7	A		
		CCT	5	6	6	9	6	6	6	6	6	5	6	7	6	6	5	6	8	6	M		
		Stress Imaging	5	5	5	9	5	5	6	5	4	4	6	5	3	5	5	6	7	5	M		
	91. Routine surveillance (1-2 years) in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	6	9	A			
		TEE	3	3	3	5	5	2	2	3	3	3	2	2	3	3	3	5	5	3	R		
		CMR	3	3	3	2	4	3	1	3	3	3	3	3	3	3	3	5	6	3	R		
		CCT	2	2	2	2	2	2	1	2	3	2	2	3	3	3	2	3	5	2	R		
	92. Routine surveillance (3-5 years) in an asymptomatic patient with no or mild sequelae	TEE	5	4	4	5	5	4	2	4	3	8	3	3	3	3	5	6	7	4	M		
		CMR	5	5	5	5	5	5	1	5	4	4	4	5	7	5	5	7	9	5	M		
		CCT	3	3	3	5	5	3	1	6	4	3	3	4	4	3	4	5	6	4	M		
	93. Routine surveillance (6-12 months) in an asymptomatic child with valvular or ventricular dysfunction or arrhythmia	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
		CMR	4	4	4	5	5	4	3	4	3	4	2	5	5	4	4	6	9	4	M		
		CCT	3	3	3	5	3	3	3	3	3	3	1	5	5	3	3	4	7	3	R		
	94. Routine surveillance (1-2 years) in an asymptomatic adult with valvular or ventricular dysfunction or arrhythmias	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
		TEE	6	5	5	9	5	5	4	5	4	5	3	4	5	5	5	6	7	5	M		
		CMR	5	5	5	9	5	5	5	5	6	5	3	5	5	5	5	7	9	5	M		
CCT		3	3	3	9	3	3	3	3	6	3	3	5	5	3	2	5	6	3	R			
95. Routine surveillance (3-12 months) in a patient with symptoms of heart failure and/or atrial arrhythmias	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A			
	CMR	5	5	5	5	5	5	6	5	4	5	5	5	3	5	5	6	9	5	M			
	CCT	3	3	5	5	3	3	3	3	4	3	4	5	3	3	3	4	7	3	R			

Table 8: Pulmonary Stenosis (PS)

Unrepaired	96. Routine surveillance (3-6 months) in an asymptomatic infant with mild PS	TTE	9	8	8	9	9	6	9	7	3	8	7	8	9	7	8	7	5	8	A
	97. Routine surveillance (1-2 years) in an asymptomatic child with mild PS	TTE	7	7	8	9	9	8	9	8	7	9	7	9	9	8	9	9	5	8	A

98. Routine surveillance (3-5 years) in an asymptomatic adult with mild PS	TTE	9	8	8	9	9	8	9	8	9	9	8	9	9	8	8	9	6	9	A
	CMR	4	3	3	5	5	3	3	3	1	4	2	3	9	3	5	6	4	3	R
	CCT	3	3	3	5	3	3	3	3	1	4	1	3	5	3	4	4	4	3	R
99. Routine surveillance (3-6 months) in an asymptomatic infant with ≥ moderate PS	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	7	9	A
	CMR	4	3	6	1	3	3	3	3	1	4	3	3	3	3	3	4	5	3	R
	CCT	3	3	6	1	2	2	3	3	1	4	2	3	3	3	3	2	3	3	R
100. Routine surveillance (1-2 years) in an asymptomatic child or adult with ≥ moderate PS	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	6	9	A
	CMR	4	4	5	5	6	4	5	4	1	5	4	3	6	5	6	7	6	5	M
	CCT	3	4	4	5	3	4	3	4	1	5	3	3	4	5	5	4	4	4	M
101. Routine surveillance (3-5 years) in an asymptomatic adult with PS and pulmonary artery dilation	CMR	4	7	8	9	7	6	6	7	7	6	7	5	9	7	6	8	7	7	A
	CCT	3	5	7	9	5	6	6	6	4	6	6	5	6	7	5	7	5	6	M
102. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	5	6	6	9	7	5	6	6	6	6	8	6	9	6	6	8	8	6	M
	CCT	4	5	6	9	5	5	6	5	4	5	8	6	6	6	5	7	7	6	M
	Stress Imaging	3	3	5	9	6	5	7	4	6	4	5	6	3	6	3	7	7	5	M
103. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	A
	TEE	6	5	6	9	7	5	6	7	6	5	5	5	9	5	6	6	9	6	M
	CMR	5	6	6	9	7	6	6	6	3	6	5	6	9	5	5	7	7	6	M
	CCT	3	6	6	9	4	6	6	4	3	6	5	6	6	5	4	5	7	6	M
Post-procedural: Surgical or Catheter-based	104. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
	105. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	5	5	6	9	6	5	5	5	6	4	6	5	6	5	5	7	8	5	M
	CMR	6	6	6	9	6	7	7	6	6	6	6	5	6	6	6	8	9	6	M
	CCT	5	5	6	9	5	5	6	5	6	5	6	5	3	5	5	6	6	5	M
	Stress Imaging	4	4	4	9	4	5	6	4	3	4	4	5	1	5	4	6	5	4	M
106. Routine surveillance (1-2 years) in an asymptomatic child with no or mild sequelae	TTE	9	8	7	9	8	8	9	8	9	9	8	9	9	9	8	9	7	9	A
	CMR	3	3	3	5	3	3	3	3	3	3	2	3	6	3	3	6	7	3	R
	CCT	3	3	3	5	2	2	3	3	3	3	1	3	3	3	2	3	5	3	R
107. Routine surveillance (3-5 years) in an asymptomatic adult with no or mild sequelae	TTE	9	9	8	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	A
	CMR	4	4	3	9	5	4	3	4	3	4	2	5	6	4	4	6	9	4	M
	CCT	3	3	3	9	3	3	3	3	3	3	1	5	3	4	3	4	6	3	R

108. Routine surveillance (6-12 months) in an asymptomatic child with moderate or severe sequelae	TTE	9	9	9	9	8	9	9	9	9	9	9	9	9	9	8	9	9	9	A
	CMR	4	6	6	5	3	5	5	5	6	6	4	4	6	5	4	5	9	5	M
	CCT	3	4	6	5	3	4	5	4	6	5	4	4	3	5	3	3	7	4	M
109. Routine surveillance (1-3 years) in an asymptomatic adult with moderate or severe sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	A
	CMR	5	7	7	9	7	7	7	7	6	6	7	7	9	5	5	7	9	7	A
	CCT	5	5	7	9	6	5	6	5	6	4	6	7	5	5	4	6	7	6	M
110. Routine surveillance (3-12 months) in a patient with heart failure symptoms	Stress Imaging	4	5	7	9	3	5	7	4	7	4	4	7	4	6	4	6	7	5	M
	TTE	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	9	8	9	A
	CMR	5	5	5	9	7	5	3	5	3	5	5	5	3	5	5	7	8	5	M
	CCT	4	4	4	9	6	4	3	4	3	4	4	5	3	5	4	5	7	4	M

Table 9: Pulmonary Atresia with IntaCCT Ventricular Septum (PA/IVS)

Unrepaired	111. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	6	5	5	9	6	4	4	8	6	5	6	4	9	4	7	4	7	6	M
		CMR	6	6	6	9	6	5	6	7	6	6	7	6	9	5	6	7	9	6	M
		CCT	5	6	5	9	5	4	6	5	6	6	6	6	6	5	5	6	7	6	M
		Lung Scan	5	3	3	9	3	4	6	6	6	1	6	6	1	5	6	5	7	5	M
Post-procedural: Palliation	112. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	7	9	9	9	9	9	9	9	9	9	9	A	
		Lung Scan	4	3	3	5	7	5	4	2	3	1	7	5	4	5	6	4	6	4	M
Post-procedural: Complete Repair	113. Routine surveillance (1-3 months) in an asymptomatic patient 114. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	8	5	9	9	9	6	9	3	9	9	9	7	6	9	5	9	A
		TEE	5	6	5	9	7	6	3	5	6	5	5	4	6	5	6	6	8	6	M
		CMR	6	7	6	9	8	6	6	6	6	5	5	6	6	5	6	7	9	6	M
		CCT	5	6	5	9	7	6	6	5	6	5	5	6	4	5	5	7	8	6	M
		Stress imaging	4	4	6	9	3	3	3	4	6	5	5	6	3	5	4	7	8	5	M
		Lung Scan	1	4	6	9	7	5	5	4	6	1	5	6	3	5	5	7	8	5	M
Post-procedural: Complete Repair	115. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	5	6	6	9	6	3	4	5	6	4	5	4	9	5	6	6	8	6	M
		CMR	6	7	6	9	5	4	6	6	7	7	5	6	9	6	6	7	9	6	M
		CCT	4	6	6	8	5	3	6	6	7	7	5	6	9	6	5	7	8	6	M
		Lung Scan	4	4	5	9	2	4	6	4	7	1	5	4	3	6	5	4	8	4	M
Post-procedural: Complete Repair	116. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	7	9	9	9	9	9	9	9	9	9	A	
		Lung Scan	3	3	3	5	7	2	9	3	3	1	5	5	7	5	6	4	6	5	M

117. Evaluation due to a change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	5	5	6	9	7	6	3	5	4	5	4	4	6	5	6	7	8		5	M
	CMR	6	6	6	9	7	6	6	7	4	6	6	6	6	6	6	7	9		6	M
	CCT	5	5	6	9	7	5	6	5	4	5	6	6	6	6	5	6	7		6	M
	Stress imaging	4	5	5	9	3	4	4	4	5	4	4	6	3	6	4	5	9		4	M
	Lung Scan	3	4	4	9	7	4	6	4	4	1	5	5	6	6	5	4	8		5	M
118. Routine surveillance (3-6 months) in an asymptomatic infant	TTE	9	9	8	9	9	9	8	9	5	9	9	9	9	8	9	7		9	A	
	CMR	3	4	3	1	3	2	3	3	3	4	2	3	4	3	5	5	7	3	R	
	CCT	3	3	3	1	2	1	3	3	3	4	2	3	3	3	4	3	4	3	R	
	Lung Scan	3	1	3	1	2	1	3	3	3	1	3	3	3	5	4	2	4	3	R	
119. Routine surveillance (1-2 years) in an asymptomatic child with no or mild sequelae	TTE	9	9	8	9	9	9	8	9	8	9	9	9	9	9	9	7		9	A	
	CMR	4	4	3	1	4	5	4	3	3	3	4	3	6	3	6	5	7	4	M	
	CCT	4	3	3	1	3	4	3	3	3	3	4	3	4	3	5	3	4	3	R	
	Lung Scan	3	1	3	1	5	3	3	3	3	1	3	3	4	5	4	3	4	3	R	
120. Routine surveillance (2-3 years) in an asymptomatic adult with no or mild sequelae	TTE	9	9	8	9	8	9	9	9	8	9	9	9	9	9	9	9		9	A	
	CMR	4	4	4	5	7	7	4	5	3	5	4	3	7	3	6	6	9	5	M	
	CCT	4	3	4	5	6	5	4	5	3	4	4	3	4	3	5	5	7	4	M	
	Lung Scan	3	1	3	5	7	3	3	3	3	1	3	3	4	5	4	4	5	3	R	
121. Routine surveillance (6-12 months) in an asymptomatic child with ≥ moderate sequelae	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9		9	A	
	CMR	5	6	4	5	7	5	4	5	3	4	5	4	6	5	6	4	7	5	M	
	CCT	4	4	4	5	6	5	3	4	3	4	4	4	4	5	4	3	6	4	M	
	Lung Scan	4	3	4	5	7	3	3	3	3	1	4	4	4	5	4	2	6	4	M	
122. Routine surveillance (1-3 years) in an asymptomatic adult with ≥ moderate sequelae	TTE	9	9	8	9	9	9	8	9	9	9	9	9	9	9	9	9		9	A	
	TEE	6	4	3	9	6	6	3	5	6	4	5	5	7	5	6	6	6	6	M	
	CMR	6	7	4	9	8	7	6	7	9	6	7	6	7	6	6	7	9	7	A	
	CCT	5	5	4	9	7	5	4	5	9	4	6	6	7	6	5	5	7	5	M	
	Lung Scan	4	3	4	9	7	3	3	5	4	3	5	5	7	5	4	4	7	4	M	
123. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9		9	A	
	CMR	7	5	4	5	7	4	3	5	4	4	6	6	6	6	5	7	9	5	M	
	CCT	6	4	4	5	6	3	3	4	4	4	5	6	4	6	4	7	7	4	M	

Table 10: Mitral Valve Disease

Unrepaired: Congenital Mitral Stenosis (MS)	124. Routine surveillance (1-4 weeks) in an infant with mild MS	TTE	8	7	8	7	6	9	9	8	9	7	9	9	9	9	7	8	8	A
---	---	-----	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

Unrepaired: Congenital Mitral Regurgitation (MR) including Mitral Valve Prolapse (MVP)	125. Routine surveillance (3-6 months) in an infant with mild MS	TTE	8	9	5	7	6	7	7	7	9	3	9	9	7	9	9	8	8	8	A
	126. Routine surveillance (1-3 months) in an infant with ≥ moderate MS	TTE	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	A
	127. Routine surveillance (1-2 years) in an asymptomatic child with mild MS	TTE	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	7	9	A
	128. Routine surveillance (3-12 months) in an asymptomatic child with ≥ moderate MS	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		Stress Imaging	4	4	4	9	1	1	6	4	9	3	4	4	3	4	4	5	4	4	M
	129. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	7	7	7	9	7	6	9	7	4	8	7	6	6	5	6	7	8	7	A
		CMR	5	5	4	9	6	5	5	5	3	5	6	5	6	5	6	7	9	5	M
		CCT	4	4	4	9	4	4	5	4	3	4	6	4	6	5	4	4	6	4	M
		Stress Imaging	4	5	4	9	6	4	4	5	4	4	5	5	3	5	5	6	7	5	M
130. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	7	7	8	9	7	4	9	7	9	6	7	7	7	7	7	7	9	7	A	
	CMR	5	5	5	9	5	4	5	5	4	4	6	5	7	5	5	7	9	5	M	
	CCT	4	4	4	9	5	3	5	4	4	4	6	5	7	5	4	6	7	5	M	
	Stress Imaging	3	1	4	9	4	2	4	3	4	3	5	4	3	3	3	6	7	4	M	
Unrepaired: Congenital Mitral Regurgitation (MR) including Mitral Valve Prolapse (MVP)	131. Routine surveillance (6-12 months) in an asymptomatic infant with mild MR	TTE	9	9	9	9	9	8	9	9	3	9	8	9	9	9	8	5	9	A	
	132. Routine surveillance (1-3 months) in an asymptomatic infant with ≥ moderate MR	TTE	9	9	9	9	9	9	9	9	4	9	9	9	9	9	9	7	9	A	
	133. Routine surveillance (2-5 years) in a child with mild MR, normal LV size and systolic function	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A	
		CMR	4	3	3	5	3	3	3	3	3	2	3	7	3	6	5	3	3	R	
		CCT	3	2	2	5	1	2	3	2	3	2	1	2	5	3	5	4	3	3	R
	134. Routine surveillance (6-12 months) in a child with ≥ moderate MR	TTE	9	9	9	9	9	9	9	9	7	9	9	9	9	9	9	6	9	A	
		CMR	4	4	4	5	6	4	3	4	3	4	2	5	6	5	6	7	3	4	M
		CCT	3	3	3	5	1	3	3	3	3	3	1	4	5	4	4	4	3	3	R
	135. Routine surveillance (annually) in an asymptomatic child with MVP and mild MR	TTE	6	4	4	5	9	3	4	8	4	4	6	5	5	5	3	9	5	5	M
	136. Routine surveillance (2-5 years) in an asymptomatic child with MVP and mild MR	TTE	7	9	8	9	9	9	9	9	8	9	9	9	9	9	9	7	9	A	

137. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	6	6	6	9	8	6	6	6	6	6	8	6	7	5	6	8	9		6	M
	CMR	6	6	5	5	7	6	5	6	7	6	6	6	7	6	6	8	9		6	M
	CCT	4	4	5	5	6	4	5	4	7	4	4	6	6	6	4	5	6		5	M
	Stress Imaging	4	5	5	9	7	5	6	5	6	5	6	6	1	5	4	5	7		5	M
138. Evaluation prior to planned repair	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	7	7	7	9	7	6	9	7	6	7	8	7	9	7	7	7	9	7	A	
	CMR	5	5	5	5	6	5	5	5	7	5	6	5	7	5	5	7	9	5	M	
	CCT	4	4	5	5	5	3	5	4	7	4	4	5	6	5	4	5	7	5	M	
	Stress Imaging	3	3	3	9	3	3	3	3	6	3	3	4	1	3	3	5	7	3	R	
Post-procedural: Surgical or Catheter-based	139. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
140. Evaluation in an infant or child due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	6	7	7	1	8	6	9	6	3	7	7	6	6	7	7	7	7	7	A	
	CMR	5	5	4	5	6	6	5	5	3	3	6	6	6	4	5	7	9	5	M	
	CCT	5	4	4	5	5	5	4	5	3	4	6	6	4	3	3	5	6	5	M	
	Stress Imaging	4	3	3	5	2	5	4	5	3	3	6	6	1	3	3	5	6	4	M	
	Fluoro	5	5	8	9	7	5	7	7	7	6	8	5	6	7	7	8	5	7	A	
141. Routine surveillance (3-6 months) in an infant with mild MS or MR and no LV dysfunction	TTE	9	9	8	9	9	9	9	9	6	9	8	9	9	9	9	9	6	9	A	
	142. Routine surveillance (1-3 months) in an infant with ≥ moderate MS or MR, dilated LV, and no LV dysfunction	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	4	3	3	1	5	3	3	3	3	4	3	3	3	3	3	4	3	R	
		CMR	4	3	3	5	4	3	3	3	3	3	3	3	3	3	3	9	3	R	
		CCT	4	3	3	1	2	2	3	3	3	3	2	3	3	3	2	1	5	R	
143. Routine surveillance (1-2 years) in a child with mild MS or MR and no LV dysfunction	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	5	9	A	
	144. Routine surveillance (3-12 months) in a child with ≥ moderate MS or MR, dilated LV, and no LV dysfunction	TTE	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	7	9	A	
		TEE	4	3	3	5	3	3	3	3	3	4	3	3	3	3	4	5	3	R	
		CMR	4	3	3	5	3	3	3	3	3	3	3	3	3	3	4	7	3	R	
		CCT	4	3	3	5	2	3	3	3	3	3	2	3	3	3	2	2	5	R	
Stress Imaging	3	4	3	5	3	3	3	3	3	3	2	4	3	3	3	4	5	3	R		
145. Routine surveillance (annually) in a child with normal prosthetic mitral valve function and no LV dysfunction	TTE	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	5	9	A		

146. Routine surveillance (3-12 months) in a child with prosthetic mitral valve or ventricular dysfunction, and/or arrhythmia	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	6	5	5	5	6	5	4	6	3	5	4	4	6	5	5	4	7	5	M	
	CMR	6	5	5	5	5	5	4	5	3	4	3	5	6	5	5	4	9	5	M	
	CCT	5	4	4	5	4	4	3	4	3	4	2	5	3	5	4	2	4	4	M	

Table 11: Left Ventricular Outflow TracCT (LVOT) Lesions

Unrepaired: Subvalvular Aortic Stenosis	147. Routine surveillance (1-3 months) in an infant with any degree of subvalvular AS and ≤ mild AR	TTE	9	9	9	9	9	9	9	9	6	9	9	9	9	7	9	9	7	9	A
	148. Routine surveillance (1-2 years) in a child or adult with mild subvalvular AS and no AR	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	5	9	A
	149. Routine surveillance (6-12 months) in a child or adult with ≥ moderate subvalvular AS and/or ≤ mild AR	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
		TEE	6	3	3	7	8	3	3	1	5	4	4	3	3	5	6	5	5	4	M
		CMR	5	4	4	5	5	5	3	5	1	4	3	3	3	5	6	4	5	4	M
		CCT	3	3	4	5	3	4	3	4	1	3	2	3	3	5	5	3	5	3	R
		Stress Imaging	3	1	4	5	1	4	3	1	4	1	2	3	1	5	5	4	5	3	R
	150. Routine surveillance (3-5 years) in an asymptomatic adult with ≥ moderate subvalvular AS	CCT	3	4	6	5	3	6	3	4	6	3	2	5	3	5	4	3	6	4	M
		Stress Imaging	5	3	7	5	2	5	6	1	7	4	4	5	1	7	4	4	6	5	M
	151. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	5	6	6	9	8	6	6	6	9	4	7	6	7	5	6	7	8	6	M
		CMR	5	7	6	9	8	7	7	7	9	6	7	6	7	5	7	7	9	7	A
		CCT	3	6	6	9	5	6	7	7	9	6	7	6	7	5	6	7	9	6	M
		Stress Imaging	5	5	6	9	6	6	7	4	6	7	7	5	5	5	5	7	8	6	M
	152. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	5	7	7	9	8	5	6	7	7	5	7	6	7	7	9	6	8	7	A
		CMR	5	7	7	9	7	6	6	7	4	7	7	6	7	5	7	6	8	7	A
		CCT	3	6	7	9	5	6	6	7	4	7	7	6	7	5	7	4	8	6	M
		Stress Imaging	4	3	7	9	3	1	3	3	4	1	5	6	1	6	3	5	6	4	M
Post-operative	153. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	7	9	9	9	9	9	9	9	9	9	A	
	154. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	7	6	7	9	8	6	6	7	3	5	7	5	7	7	6	7	9	7	A
		CMR	6	7	6	9	6	6	6	6	4	7	6	6	7	5	7	7	9	6	M
		CCT	6	5	6	9	5	5	6	6	4	7	6	6	7	5	7	6	9	6	M
		Stress Imaging	5	5	5	9	5	5	6	3	4	7	5	6	5	6	7	5	8	5	M

Unrepaired: Aortic Valve Stenosis and/or Regurgitation	155. Routine surveillance (3-6 months) in an infant with \leq mild stenosis and/or AR	TTE	9	9	8	9	9	9	9	9	9	4	9	7	9	9	9	9	9	6	9	A
	156. Routine surveillance (1-3 months) in an infant with \geq moderate stenosis and/or AR	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	157. Routine surveillance (1-2 years) in a child or adult with \leq mild stenosis and/or AR	TTE	9	9	8	9	9	8	9	9	9	9	8	9	9	9	9	9	9	6	9	A
		TEE	3	3	3	5	6	5	3	3	6	3	2	3	5	5	3	3	3	3	R	
		CMR	5	3	3	1	5	5	1	3	3	1	2	3	5	5	3	3	4	3	R	
		CCT	4	2	3	1	3	4	1	1	3	1	1	3	4	5	3	2	4	3	R	
		Stress Imaging	4	2	3	5	2	3	1	1	3	1	1	5	3	3	3	2	3	3	R	
	158. Routine surveillance (6-12 months) in a child or adult with \geq moderate stenosis and/or AR	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A	
		TEE	5	3	5	5	6	5	1	5	4	5	4	3	5	6	4	6	5	5	M	
		CMR	6	5	5	5	6	5	1	5	3	5	4	5	5	5	5	4	6	5	M	
		CCT	4	4	4	5	3	5	1	5	3	4	4	5	5	5	4	4	6	4	M	
		Stress Imaging	4	1	5	5	3	4	6	4	4	4	5	6	3	6	3	4	4	4	M	
	159. Routine surveillance (3-12 months) in an adult with heart failure symptoms or \geq moderate stenosis and/or AR	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	6	6	5	9	7	6	1	6	5	6	6	3	5	6	6	7	6	6	M	
	CMR	6	6	5	5	7	6	1	6	7	6	6	5	5	5	6	7	8	6	M		
	CCT	4	5	5	5	4	6	1	5	7	4	6	5	5	5	5	8	5	M			
	Stress Imaging	4	6	5	5	2	5	4	4	7	5	6	5	3	6	6	5	5	5	M		
	TTE	9	9	9	9	9	9	9	9	7	9	9	9	9	9	9	9	8	9	A		
	TTE	9	9	8	9	9	9	9	9	4	9	9	9	9	9	9	9	7	9	A		
	TTE	9	9	9	9	9	9	9	9	7	9	8	9	9	9	9	9	9	A			
	TTE	7	3	3	5	6	2	2	4	3	3	3	3	3	1	3	5	3	R			
	TTE	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	7	9	A			
	CMR	6	2	3	5	3	5	3	3	3	1	3	3	7	3	4	4	3	R			
	CCT	5	1	3	5	2	3	3	3	3	1	2	3	6	3	3	4	3	R			

165. Routine surveillance (6-12 months) in an asymptomatic child with \geq moderate AS and/or \geq moderate AR	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	6	5	3	5	3	5	1	5	6	5	4	5	6	5	5	4	6	5	M	
	CCT	5	3	3	5	1	4	1	4	6	4	4	5	5	5	4	3	6	4	M	
	Stress Imaging	4	4	3	5	1	1	4	2	6	1	4	4	1	5	4	3	6	4	M	
166. Routine surveillance (3-5 years) in a child with a bicuspid aortic valve with trivial or mild valvular dysfunction with no aortic sinus and/or ascending aortic dilation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	5	5	5	5	3	5	1	5	3	4	6	5	6	3	5	5	6	5	M	
	CCT	4	4	5	5	1	4	1	3	3	4	3	5	6	3	4	3	5	4	M	
167. Routine surveillance (2-3 years) in a child with aortic sinus and/or ascending aortic dilation with stable z-scores	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	7	7	7	5	7	7	9	5	4	7	7	7	6	6	7	7	6	7	A	
	CCT	6	6	7	5	6	6	9	4	4	6	6	7	6	6	5	5	5	6	M	
168. Routine surveillance (6-12 months) in a child with aortic sinus and/or ascending aortic dilation with increasing z-scores	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	8	8	9	9	8	8	9	8	9	8	8	7	6	7	8	7	8	8	A	
	CCT	7	7	9	9	7	7	9	7	9	7	7	7	6	7	6	5	8	7	A	
169. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	6	6	7	9	7	6	5	6	9	6	7	6	6	6	6	6	7	6	M	
	CMR	7	7	6	9	7	7	5	7	9	7	6	6	6	7	7	7	8	7	A	
	CCT	7	6	6	9	7	7	5	7	9	7	6	6	6	6	7	6	8	7	A	
	Stress Imaging	5	5	6	9	6	5	5	3	9	4	6	6	1	5	7	6	8	6	M	
170. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	7	7	7	5	5	7	5	7	9	7	8	7	8	6	7	7	9	7	A	
	CMR	7	7	6	9	7	7	4	7	9	7	6	7	8	7	7	7	9	7	A	
	CCT	7	6	6	9	8	7	4	7	9	7	6	7	8	7	7	5	9	7	A	
	Stress Imaging	3	3	6	9	2	3	2	3	9	2	6	3	1	3	5	5	7	3	R	
Post-procedural: Surgical or Catheter-based	171. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	172. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	7	7	7	9	6	7	6	7	4	6	7	6	6	7	7	7	7	A	
		CMR	7	7	6	9	7	7	4	7	9	7	7	6	6	7	7	7	7	A	
		CCT	7	7	6	9	8	7	4	7	9	7	7	6	6	7	7	6	6	A	
		Stress Imaging	6	6	6	9	7	6	5	6	6	5	6	1	7	6	5	7	6	M	
		Fluoro	7	7	6	9	7	7	7	7	9	7	6	6	1	7	5	7	8	A	

	173. Routine surveillance (3-6 months) in an infant following neonatal intervention with ≤ mild AS and/or AR and no LV dysfunction	TTE	9	9	8	9	9	9	9	9	9	6	9	9	9	9	9	9	9	6	9	A
	174. Routine surveillance (1-3 months) in an infant following neonatal intervention with ≥ moderate AS and/or regurgitation, and/or LV dysfunction	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	175. Routine surveillance (1-2 years) in a child with ≤ mild AS and/or AR following repair or normal prosthetic valve function	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	6	9	A
	176. Routine surveillance (6-12 months) in a child with ≥ moderate AS or AR	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A
		TEE	5	5	6	5	6	5	3	5	3	5	5	4	6	5	5	4	4	5	M	
		CMR	5	5	6	5	6	5	3	5	4	5	4	5	6	5	5	3	6	5	M	
		CCT	5	5	6	5	5	5	3	5	4	5	3	5	4	5	4	3	5	5	M	
		Stress Imaging	4	4	6	5	4	4	4	4	6	4	3	4	1	5	4	4	5	4	M	
	177. Routine surveillance (3-12 months) in a child with heart failure symptoms and/or ventricular dysfunction	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	6	6	5	5	8	6	3	6	6	6	4	6	6	6	5	6	7	6	M	
		CCT	5	5	5	5	7	5	3	6	6	4	4	6	6	6	4	3	5	5	M	
		Stress Imaging	4	6	5	5	6	6	3	5	7	6	3	6	1	6	4	4	6	5	M	
Unrepaired: Supravalvular Aortic Stenosis	178. Routine surveillance (3-6 months) in an infant with any degree of supravalvular AS	TTE	9	9	9	9	9	9	9	9	7	9	9	9	9	9	9	9	9	9	A	
	179. Routine surveillance (1-2 years) in an asymptomatic child or adult with mild supravalvular AS	TTE	9	9	9	9	9	9	9	9	7	9	9	9	9	9	9	9	9	9	A	
	180. Routine surveillance (6-12 months) in an asymptomatic child or adult with moderate supravalvular AS	TTE	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	A	
	181. Routine surveillance (2-5 years) in an asymptomatic adult with moderate supravalvular AS	TEE	4	4	6	5	7	6	3	3	6	4	4	4	6	5	7	5	6	5	M	
		CMR	5	5	6	9	7	6	7	5	4	5	4	6	6	7	6	5	9	6	M	
		CCT	5	4	6	9	6	5	7	4	4	5	3	6	6	7	4	4	8	5	M	
		Stress Imaging	4	4	6	9	5	5	6	3	3	4	4	5	6	6	5	4	6	5	M	
	182. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	7	5	5	5	8	6	4	5	6	5	7	6	7	5	5	7	9	6	M	
		CMR	7	7	7	9	8	7	9	7	9	7	7	6	7	7	7	7	9	7	A	

		CCT	6	7	7	9	8	7	9	7	9	7	7	6	7	7	7	7	9	7	A
		Stress Imaging	5	6	6	9	7	6	9	6	6	6	7	6	7	6	6	5	6	6	M
	183. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	6	5	6	9	4	3	6	5	9	5	5	7	9	5	5	6	9	6	M
		CMR	6	7	7	9	7	8	9	7	9	7	7	7	9	7	7	7	9	7	A
		CCT	5	8	7	9	8	8	9	8	9	8	7	7	7	7	7	9	8	A	
Post-operative	184. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	185. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	6	5	6	5	8	5	6	5	6	5	6	6	6	5	5	6	9	6	M
		CMR	6	7	7	9	8	7	7	7	9	7	7	6	6	7	7	7	9	7	A
		CCT	5	8	7	9	7	7	7	8	9	7	7	6	4	7	7	7	9	7	A
		Stress Imaging	5	7	6	9	6	7	7	7	3	7	5	6	4	7	7	6	9	7	A
	186. Routine surveillance (2-5 years) in a patient with no or mild supralvalvular AS	TTE	9	8	9	9	9	8	9	8	9	8	9	9	9	8	9	9	9	9	A
		TEE	3	3	3	5	4	1	3	3	6	1	3	3	3	3	3	4	4	3	R
		CMR	3	4	5	9	6	4	5	4	3	4	4	3	3	4	4	5	5	4	M
		CCT	3	4	5	9	3	4	5	4	3	4	4	3	3	4	4	5	5	4	M
		Stress Imaging	3	3	3	9	3	3	5	2	4	3	2	4	1	3	3	5	5	3	R
	187. Routine surveillance (6-12 months) in a patient with ≥ moderate supralvalvular AS	TTE	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	A
		TEE	4	3	5	5	4	4	3	3	5	3	3	3	6	3	3	5	4	4	M
		CMR	4	4	5	5	8	6	5	5	6	4	4	5	6	5	5	6	6	5	M
		CCT	4	3	5	5	3	6	5	4	6	4	2	5	6	5	5	5	6	5	M
		Stress Imaging	4	3	3	9	4	6	5	2	6	4	4	5	4	4	4	5	5	4	M

Table 12: Aortic Coarctation/ Interrupted Aortic Arch

Unrepaired	188. Routine surveillance (3-6 months) in an infant with mild aortic coarctation in the absence of a PDA	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	189. Routine surveillance (1-2 years) in a child or adult with mild aortic coarctation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	3	3	3	5	7	3	3	3	3	3	3	3	3	3	5	8	3	R	
		CCT	3	3	3	5	7	3	3	3	3	3	3	3	3	3	3	8	3	R	
	190. Routine surveillance (3-5 years) in a child or adult with mild aortic coarctation	TTE	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	A
		CMR	4	8	8	9	8	8	7	8	9	8	8	7	6	7	8	7	9	8	A
		CCT	4	7	8	9	8	7	7	7	9	7	8	7	6	7	7	6	9	7	A
	191. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	4	4	3	3	4	4	4	4	7	4	5	5	6	4	4	4	8	4	M
		CMR	7	8	7	9	8	8	8	8	9	8	8	7	6	8	8	8	9	8	A

192. Evaluation prior to planned repair	CCT	7	7	7	9	8	7	8	7	9	7	8	7	6	8	7	8	9	7	A
	Stress Imaging	3	6	5	9	3	6	8	5	6	5	5	6	6	6	6	5	8	6	M
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	7	8	8	9	8	8	9	8	9	8	8	7	8	8	8	8	9	8	A
	CCT	7	8	8	9	8	8	9	8	9	8	8	7	6	8	7	7	9	8	A
Post-procedural: Surgical or Catheter-based	193. Routine post-procedural evaluation (within 30 days)	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	6	3	3	3	5	2	6	3	3	3	3	3	3	8	7	7	3	R	
	CCT	5	3	3	3	6	2	6	3	3	3	3	3	3	7	7	7	3	R	
194. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	7	4	4	5	4	4	4	4	6	4	6	4	5	4	4	4	9	4	M
	CMR	7	7	8	9	8	7	8	7	9	7	7	7	7	8	7	8	9	7	A
	CCT	7	7	8	9	7	7	8	7	9	7	8	7	7	8	7	8	9	7	A
	Fluoro	6	5	4	5	7	5	6	5	9	5	6	2	1	3	5	8	9	5	M
195. Routine surveillance (3-6 months) within the first year following surgical or catheter-based intervention in an asymptomatic patient with no or mild sequelae	TTE	6	9	9	9	9	9	9	9	6	9	9	9	9	4	9	9	9	9	A
	CMR	6	3	6	8	3	8	3	8	3	6	4	3	5	9	5	5	7	5	M
196. Routine surveillance (6-12 months) within the first year following catheter-based intervention in an asymptomatic patient with no or mild sequelae	CCT	6	3	6	9	3	8	3	8	3	6	4	3	5	9	5	6	7	6	M
	TTE	9	4	3	9	9	9	3	9	7	4	9	9	9	4	4	9	9	9	A
197. Routine surveillance (6 months) after the first year following surgical or catheter-based intervention in an asymptomatic patient with no or mild sequelae	TTE	9	9	7	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	6	5	3	5	5	3	4	5	3	5	4	2	3	5	5	7	6	5	M
	CCT	5	4	3	5	4	3	4	5	3	5	4	2	3	5	5	7	6	4	M
198. Routine surveillance (1-2 years) after the first year following surgical or catheter-based intervention in an asymptomatic patient with no or mild sequelae	CMR	8	8	8	9	5	8	9	8	9	8	8	7	7	8	8	9	9	8	A
	CCT	8	8	8	9	6	8	9	8	9	8	8	7	7	8	8	9	9	8	A
	Fluoro	4	4	4	9	2	4	7	4	9	4	7	4	1	5	4	9	6	4	M
199. Routine surveillance (3-5 years) in an asymptomatic patient to evaluate for aortic arch aneurysms, in-stent stenosis, stent fraCCTure, or endoleak	CMR	8	8	8	9	5	8	9	8	9	8	8	7	7	8	8	9	9	8	A
	CCT	8	8	8	9	6	8	9	8	9	8	8	7	7	8	8	9	9	8	A
	Fluoro	4	4	4	9	2	4	7	4	9	4	7	4	1	5	4	9	6	4	M

200. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	7	6	5	3	9	5	3	7	6	6	5	5	3	6	6	8	9	9	6	M
	CCT	6	5	5	3	7	5	3	6	6	6	5	5	3	6	5	7	9	9	5	M

Table 13: Coronary Anomalies

Unrepaired	201. Routine surveillance (annually) in an asymptomatic patient with anomalous right coronary artery from the left aortic sinus	TTE	9	3	3	3	6	3	9	3	9	3	4	3	3	3	3	9	4	3	R
		Stress Imaging	6	2	3	2	3	1	3	3	3	3	2	1	3	5	3	6	4	4	3
Unrepaired	202. Routine surveillance (2-5 years) in an asymptomatic patient with anomalous right coronary artery from the left aortic sinus	TTE	8	7	8	9	7	7	9	7	9	7	7	9	9	7	7	9	7	7	A
		CMR	5	3	7	3	3	2	3	4	2	3	2	1	3	8	1	3	4	3	R
		CCT	3	3	4	9	3	2	3	3	3	3	4	3	4	4	3	8	5	3	R
		Stress Imaging	7	7	7	9	1	7	9	7	9	7	7	7	7	7	7	7	7	7	A
		TTE	6	4	4	3	6	2	3	6	3	3	2	3	3	3	1	3	5	3	R
Unrepaired	203. Routine surveillance (annually) in an asymptomatic patient with small coronary fistula	Stress Imaging	3	3	3	5	6	3	3	3	3	4	4	3	3	3	4	5	5	3	R
		TTE	7	8	8	9	9	8	9	5	9	8	8	9	9	8	8	9	9	8	A
		CMR	3	4	4	3	3	2	3	6	2	3	2	3	3	3	5	3	5	3	R
		CCT	3	4	4	3	3	2	3	3	2	3	2	3	3	3	5	3	5	3	R
		Stress Imaging	4	3	1	3	3	2	3	7	2	3	2	2	3	5	5	5	5	3	R
Unrepaired	204. Routine surveillance (2-5 years) in an asymptomatic patient with small coronary fistula	TTE	7	9	8	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	7	5	6	9	5	5	5	5	9	5	6	5	5	5	6	8	9	5	M
		CCT	7	5	6	9	5	5	5	5	9	5	6	5	5	5	5	7	7	5	M
		Stress Imaging	6	5	5	9	5	6	7	5	9	5	5	5	5	5	5	7	7	5	M
Unrepaired	205. Routine surveillance (1-2 years) in an asymptomatic patient with moderate or large coronary fistula	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	7	7	7	9	8	7	9	7	9	7	7	7	8	7	7	8	9	7	A
		CCT	7	7	7	9	7	7	9	7	9	7	7	7	8	7	7	8	9	7	A
		Stress Imaging	7	8	7	9	8	8	9	6	9	8	7	6	8	8	8	8	9	8	A
		TTE	9	9	8	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	A
Unrepaired	206. Evaluation due to change in clinical status and/or new concerning signs or symptoms	CMR	7	7	7	9	8	7	9	7	9	7	7	7	8	7	7	8	9	7	A
		CCT	7	7	7	9	7	7	9	7	9	7	7	7	8	7	7	8	9	7	A
		Stress Imaging	7	8	7	9	8	8	9	6	9	8	7	6	8	8	8	8	9	8	A
		TTE	9	9	8	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	A
Unrepaired	207. Evaluation prior to planned repair	CMR	7	7	7	9	8	7	8	7	9	7	7	5	9	7	7	8	9	7	A
		CCT	7	7	7	9	8	7	8	7	9	7	8	5	9	7	7	8	9	7	A
		Stress Imaging	6	6	6	9	6	6	5	6	6	6	6	5	9	5	5	8	7	6	M
		TTE	9	9	8	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	A

Post-procedural: Surgical and Catheter-based	208. Routine post-procedural evaluation (within 30 days)	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	4	4	4	5	5	3	3	4	3	7	4	4	4	5	5	6	6	6	6	4	M
		CCT	5	5	4	5	6	5	3	5	3	5	4	5	4	5	5	6	6	6	6	5	M
	209. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	7	7	7	9	8	7	7	7	9	7	7	7	9	7	7	8	9	9	7	A	
		CCT	7	7	7	9	8	7	7	7	9	7	7	7	9	7	7	8	9	9	7	A	
		Stress Imaging	8	8	7	9	8	8	7	8	3	8	8	7	9	9	8	8	9	9	8	A	
	210. Evaluation within 1 year after surgery or catheter-based intervention with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A	
		CMR	6	6	5	3	6	6	6	6	3	5	3	6	6	6	6	8	6	6	6	M	
		CCT	6	6	5	9	7	6	6	6	3	5	2	6	6	6	6	8	6	6	6	M	
		Stress Imaging	4	3	3	2	6	4	3	8	4	3	5	1	7	3	5	6	7	7	4	M	
	211. Routine surveillance (1-3 months) within the first year following repair	TTE	7	7	9	9	9	3	5	7	9	1	6	2	3	5	7	9	5	7	A		
		CMR	3	3	6	1	6	1	3	3	3	1	3	2	3	3	3	4	4	3	R		
		CCT	3	3	6	5	7	1	3	3	3	1	2	2	3	3	3	4	4	3	R		
		Stress Imaging	3	3	6	5	6	1	3	2	6	1	2	2	3	3	4	4	3	3	R		
212. Routine surveillance (3-6 months) in an infant with or without ventricular or valvular dysfunction	TTE	7	9	9	9	9	8	9	9	7	8	9	9	9	9	9	6	9	A				
	CMR	3	3	3	1	8	2	3	3	6	4	3	2	5	5	4	5	3	3	R			
	CCT	3	3	3	5	6	2	3	7	6	3	2	2	5	5	3	3	3	3	R			
	Stress Imaging	3	1	2	1	8	1	3	5	6	1	2	2	5	7	1	3	3	3	R			
213. Routine surveillance (3-6 months) in a child or adult with ventricular or valvular dysfunction	TTE	8	9	9	9	9	7	9	9	7	9	9	9	9	8	9	9	9	A				
	CMR	5	6	5	5	9	3	3	8	4	5	3	4	5	7	7	5	7	5	M			
	CCT	5	6	5	5	7	3	3	7	4	4	2	4	5	7	6	3	6	5	M			
	Stress Imaging	4	7	4	9	7	1	3	6	4	5	2	3	5	7	6	3	5	5	M			
214. Routine surveillance (annually) with no or mild sequelae	TTE	9	7	5	9	8	3	6	8	6	7	5	9	9	7	7	9	6	7	A			
	CMR	3	4	3	1	6	1	3	4	3	4	3	3	3	3	3	5	4	3	R			
	CCT	3	3	3	1	6	1	3	3	3	3	2	3	3	3	2	3	3	3	R			
	Stress Imaging	4	4	3	5	7	1	3	4	3	5	2	3	3	3	3	3	3	3	R			
215. Routine surveillance (2-5 years) with no or mild sequelae	CMR	3	5	6	9	5	4	5	5	9	5	4	7	5	5	5	6	6	5	M			
	CCT	3	5	6	9	5	4	5	5	9	5	4	7	5	5	5	4	6	5	M			
	Stress Imaging	3	6	6	9	6	5	5	5	9	6	4	7	5	7	6	4	6	6	M			

Table 14: Tetralogy of Fallot (TOF)

Unrepaired	216. Routine surveillance (1-3 months) in an infant before complete repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	6	9	A
	217. Routine surveillance (1-3 months) in an infant following valvuloplasty, PDA and/or RVOT stenting, or shunt placement before complete repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A
	218. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	6	5	5	9	5	5	5	5	3	5	7	5	5	5	6	4	6	5	M
		CCT	5	4	5	9	5	5	5	5	6	4	7	5	5	5	4	5	5	5	M
	219. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	1	2	2	9	2	1	3	2	6	2	4	5	2	3	2	4	7	2	R
		CMR	5	5	5	9	5	5	6	5	3	5	5	5	5	5	5	5	8	5	M
		CCT	5	4	5	9	5	5	6	5	6	4	5	5	5	5	4	5	7	5	M
	Post-operative: Initial Repair	220. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
221. Evaluation due to change in clinical status and/or new concerning signs or symptoms		TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	6	5	5	9	5	7	5	5	6	5	6	5	6	5	5	5	7	5	M
		CMR	7	7	7	9	8	8	6	7	6	7	6	6	6	7	7	5	7	7	A
		CCT	6	6	7	9	6	8	6	6	6	5	6	6	6	7	5	5	7	6	M
		Stress Imaging	3	5	5	9	5	5	6	5	3	5	3	6	6	5	5	4	4	5	M
		Lung Scan	5	5	5	9	5	7	6	5	6	5	5	4	6	5	5	5	7	5	M
		222. Routine surveillance (annually) in an asymptomatic patient with no or mild sequelae or pulmonary regurgitation of any severity	TTE	9	8	9	9	9	9	9	9	8	6	9	9	9	9	9	7	9	A
CMR			3	3	3	9	7	3	3	7	3	3	2	3	3	3	3	5	3	R	
CCT			3	3	3	9	5	3	3	6	3	3	2	3	3	3	3	5	3	R	
Lung Scan			3	3	3	9	2	2	3	5	3	3	2	3	3	5	3	5	3	R	
223. Routine surveillance (6-12 months) in a patient with valvular dysfunction other than pulmonary valve, RVOT obstruction, branch pulmonary artery stenosis, arrhythmia or presence of a RV-to-PA conduit		TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	4	4	4	9	4	3	3	4	6	4	4	4	5	3	4	4	3	4	M
		CMR	5	5	5	5	5	5	3	5	6	5	5	5	5	5	5	6	5	M	
	CCT	5	5	5	5	5	5	3	5	6	5	5	5	5	5	4	4	5	5	M	
	Lung Scan	5	5	5	5	5	5	3	5	6	5	5	5	5	5	6	3	5	5	M	
224. Routine surveillance (2-3 years) in a patient with pulmonary regurgitation and preserved ventricular function	CMR	7	7	7	9	8	7	9	6	9	7	8	7	6	7	7	9	9	7	A	

225. Routine surveillance (3-12 months) in a patient with heart failure symptoms	CCT	6	6	7	5	7	6	6	7	9	5	6	7	6	7	5	6	7	6	M
	Lung Scan	4	3	5	2	1	1	3	3	3	3	2	2	3	3	1	8	4	3	R
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	5	5	5	5	6	5	3	5	6	5	3	6	5	5	8	5	5	5	M
	CCT	4	4	4	5	5	4	3	4	6	5	3	6	5	3	7	3	4	4	M
	Lung Scan	3	3	3	5	1	2	3	3	6	3	3	3	3	3	4	3	4	3	R
226. Evaluation prior to planned pulmonary valve replacement (percutaneous or surgical)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	5	4	5	9	2	4	4	4	6	4	4	5	5	4	5	5	7	5	M
	CMR	8	8	8	9	7	8	7	8	7	8	8	8	8	8	8	8	9	8	A
	CCT	7	7	7	9	8	8	7	7	9	6	8	8	8	8	7	7	9	8	A
	Lung Scan	4	3	2	2	1	1	3	5	2	3	2	3	3	3	1	4	4	3	R
	Post-procedural: Surgical or Catheter-based pulmonary valve replacement	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
CMR		7	3	3	5	4	3	3	3	3	3	2	3	3	3	3	5	3	R	
CCT		7	2	2	5	4	2	3	2	3	2	3	2	3	2	2	3	4	3	R
Fluoro		7	2	2	5	4	2	5	2	3	2	3	2	1	3	3	5	6	3	R
Lung scan		7	2	2	5	4	2	5	2	3	2	3	4	1	3	2	3	5	3	R
228. Evaluation due to change in clinical status and/or new concerning signs or symptoms		TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	9	5	5	9	7	5	5	5	6	5	4	5	5	5	5	5	6	5	M
	CMR	9	8	8	9	7	8	6	8	9	8	8	7	8	7	8	7	9	8	A
	CCT	9	7	7	9	8	7	6	7	9	6	7	7	8	7	7	7	7	7	A
	Stress Imaging	6	6	6	9	6	6	6	6	3	6	4	6	8	5	6	6	8	6	M
	Fluoro	7	4	5	9	7	4	6	4	6	4	6	6	1	7	4	7	9	6	M
	Lung scan	7	4	6	9	6	4	6	4	6	4	4	4	4	7	4	6	7	6	M
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
229. Evaluation at 1 year following transcatheter or surgical pulmonary valve replacement	CMR	7	3	6	5	8	8	7	3	6	1	8	7	4	3	5	9	9	6	M
	CCT	7	3	6	5	7	6	7	3	6	1	6	7	4	3	4	7	7	6	M
	Fluoro	6	4	4	5	4	6	6	4	6	1	6	4	3	5	2	6	7	5	M
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	5	9	9	9	9	A
230. Routine surveillance at 1 and 6 months in an asymptomatic patient following transcatheter pulmonary valve replacement	CMR	6	2	3	3	4	3	3	3	3	1	2	2	3	3	5	3	6	3	R
	CCT	6	2	3	3	4	2	3	3	3	1	2	2	3	3	4	1	6	3	R
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
231. Routine surveillance (annually) in an asymptomatic patient following transcatheter pulmonary valve replacement	CMR	6	3	3	5	9	5	3	3	3	1	3	2	5	3	3	4	6	3	R
	CCT	6	3	3	5	8	4	3	3	3	1	3	2	3	3	2	2	5	3	R

232. Routine surveillance (annually) in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	5	3	3	3	5	2	3	3	3	1	3	3	5	3	3	4	7	3	R	
	CCT	5	3	3	3	5	2	3	3	3	1	3	3	5	3	3	2	6	3	R	
	Lung scan	5	3	3	5	6	2	3	3	4	1	3	3	5	3	3	2	6	3	R	
233. Routine surveillance (6-12 months) in a patient with RV-PA conduit dysfunction, valvular or ventricular dysfunction, branch pulmonary artery stenosis, or arrhythmia	TTE	9	9	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	6	3	6	9	7	3	3	3	6	3	3	2	4	3	3	5	8	3	R	
	CMR	7	5	5	9	8	5	4	5	7	5	4	5	4	7	5	6	7	5	M	
	CCT	7	4	5	9	8	4	4	4	7	4	4	5	4	7	4	4	6	4	M	
	Lung scan	7	3	5	9	7	4	3	3	7	3	4	5	4	5	3	3	6	4	M	
234. Routine surveillance (2-3 years) in an asymptomatic patient with no or mild sequelae	CMR	6	4	9	9	7	7	4	5	3	3	6	7	7	7	4	8	9	7	A	
	CCT	6	4	9	9	6	6	3	4	3	3	5	7	7	7	3	7	7	6	M	
	Lung scan	6	4	6	9	7	6	3	3	3	3	4	5	7	5	3	4	6	5	M	
235. Routine surveillance (2-3 years) in a patient with valvular or ventricular dysfunction, RVOT obstruction, branch pulmonary artery stenosis, or presence of a RV-to-PA conduit	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	7	3	3	9	3	3	3	3	6	3	4	5	9	4	3	5	6	4	M	
	CMR	7	8	8	9	8	8	7	8	9	8	8	8	9	7	8	8	7	8	A	
	CCT	7	7	8	9	7	7	6	7	9	7	7	8	9	7	7	7	6	7	A	
	Lung scan	7	5	6	9	8	6	5	5	9	5	6	6	9	5	6	4	6	6	M	
236. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	9	5	5	3	7	5	3	5	4	4	4	5	3	5	5	4	7	5	M	
	CCT	9	5	5	3	6	5	3	5	4	4	3	5	3	5	4	3	5	5	M	

Table 15: Double Outlet Right Ventricle (DORV)

Unrepaired	237. Routine surveillance (1-3 months) in an infant with balanced systemic and pulmonary circulation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A
	238. Routine surveillance (3-6 months) in a child with balanced systemic and pulmonary circulation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	239. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	4	3	4	9	4	2	3	4	6	4	4	5	4	5	4	5	5	4	M
		CMR	7	7	7	9	6	6	4	7	9	7	7	5	4	7	7	5	9	7	A

240. Evaluation prior to planned repair	CCT	5	7	8	7	7	8	9	5	7	7	9	7	7	8	9	5	7	7	A	
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	3	3	3	9	7	2	4	3	9	3	4	5	5	3	3	5	7	4	M	
	CMR	7	7	7	9	8	7	6	7	9	7	7	7	6	7	7	6	9	7	A	
	CCT	7	7	7	9	8	7	6	7	9	7	7	7	6	7	7	6	5	7	A	
Post-operative	241. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	242. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	4	5	6	9	6	6	1	6	5	6	6	5	3	5	6	7	7	6	M
		CMR	7	7	7	9	8	7	6	7	6	7	7	5	4	7	7	7	9	7	A
		CCT	4	7	7	7	7	8	9	6	7	7	9	7	7	8	9	5	7	7	A
		Stress Imaging	6	5	5	9	5	5	6	5	6	4	4	5	1	5	5	4	8	5	M
		Lung Scan	6	4	4	9	3	4	6	4	6	4	4	5	1	4	4	5	8	4	M
	243. Routine surveillance (6 months) within a year following repair in an asymptomatic infant or child with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	6	9	A
	244. Routine surveillance (1-2 years) in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
	245. Routine surveillance (3-12 months) in a patient with valvular or ventricular dysfunction, right or left ventricular outflow tract obstruction, branch pulmonary artery stenosis, arrhythmia, or presence of a RV-to-PA conduit	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A
		TEE	6	4	6	5	4	3	3	4	6	4	5	4	5	5	4	4	5	4	M
		CMR	7	5	6	5	6	5	3	5	6	6	5	5	5	5	5	6	7	5	M
		CCT	7	5	6	5	6	5	3	5	6	4	5	5	5	5	5	4	6	5	M
		Stress Imaging	3	4	4	4	6	5	3	7	5	3	4	3	5	5	5	4	5	4	M
		Lung Scan	4	4	6	5	4	4	3	4	6	4	4	4	5	5	4	4	5	4	M
	246. Routine surveillance (3-5 years) in an asymptomatic patient with no or mild sequelae	TEE	1	2	3	5	4	3	3	4	6	1	3	4	5	3	3	4	5	3	R
		CMR	4	3	7	9	7	7	5	7	6	1	3	7	9	3	4	7	9	7	A
		CCT	4	2	7	9	7	6	5	6	6	1	3	7	5	3	3	6	6	6	M
		Stress Imaging	3	3	5	9	5	5	6	5	6	1	3	6	5	3	3	5	6	5	M
		Lung Scan	3	3	5	5	3	3	4	4	3	1	3	4	5	3	3	4	6	3	R
247. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	9	5	6	5	8	5	3	5	6	4	3	7	5	5	5	7	6	5	M	
	CCT	9	5	6	5	6	5	3	5	6	4	3	7	5	5	4	5	5	5	M	

Table 16: D-Loop Transposition of the Great Arteries (TGA)

Unrepaired	248. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	4	4	4	5	6	4	6	4	6	4	6	4	4	4	5	7	9	4	M
		CCT	4	4	4	5	5	4	6	4	6	4	6	4	4	4	4	7	7	4	M
	249. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	7	9	9	9	9	9	9	A
		CMR	6	4	6	5	6	6	6	7	6	4	6	4	7	7	5	7	8	6	M
		CCT	5	4	6	5	6	6	6	6	6	4	6	4	7	7	4	7	7	6	M
Post-operative: Arterial Switch Operation	250. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	251. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	7	5	6	9	6	5	6	5	6	5	6	4	6	5	5	7	7	6	M
		CMR	6	7	7	9	8	7	9	7	6	7	7	6	7	7	7	7	9	7	A
		CCT	6	7	7	9	8	7	9	7	6	7	7	6	7	7	7	7	7	7	A
		Stress Imaging	5	6	6	9	6	6	9	6	6	6	4	6	7	6	6	7	8	6	M
		Lung Scan	6	5	6	9	5	5	6	5	6	5	4	5	1	5	5	7	7	5	M
		252. Evaluation for coronary imaging in an asymptomatic patient	CMR	9	7	8	9	7	9	9	8	9	7	8	9	9	8	8	7	8	8
	CCT		8	8	8	9	9	9	9	8	9	8	8	9	9	8	8	9	9	9	A
	Stress Imaging		7	7	8	9	7	7	9	6	9	7	4	6	9	7	6	8	5	7	A
	253. Routine surveillance (1-3 months) in an asymptomatic infant with moderate sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	6	9	A
	254. Routine surveillance (3-6 months) in an asymptomatic infant with no or mild sequelae	TTE	9	9	9	9	9	9	9	8	9	8	9	9	9	9	9	9	7	9	A
	255. Routine surveillance (3-12 months) in an asymptomatic child or adult with valvular or ventricular dysfunction, right or left ventricular outflow tract obstruction, branch pulmonary artery stenosis, or arrhythmia	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	6	6	6	3	5	6	3	7	9	4	3	6	7	7	5	7	7	6	M
		CCT	6	6	6	3	5	6	3	7	9	4	3	6	7	7	4	4	6	6	M
		Stress Imaging	6	4	6	3	3	5	5	6	4	2	4	6	7	7	3	4	6	5	M
		Lung Scan	6	4	6	3	3	4	4	3	3	4	3	6	7	7	3	3	6	4	M
	256. Routine surveillance (1-2 years) in an asymptomatic child or adult with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	A
		CMR	4	4	6	1	4	5	4	5	3	4	4	3	4	5	5	6	7	4	M
		CCT	4	4	6	1	4	4	4	4	3	4	4	3	4	5	4	4	6	4	M
		Stress Imaging	4	3	6	1	2	3	7	3	3	3	4	3	4	3	3	4	6	3	R
Lung Scan		4	3	6	1	1	3	4	3	3	1	3	4	4	3	3	4	6	3	R	

257. Routine surveillance (3-5 years) in an asymptomatic patient	TEE	4	4	3	5	2	4	3	4	4	4	2	4	4	5	4	5	5	4	M	
	CMR	4	8	7	9	8	7	7	8	6	8	7	7	7	7	6	7	9	7	A	
	CCT	4	8	7	9	7	7	7	8	6	8	7	7	7	7	5	5	9	7	A	
	Stress Imaging	4	6	7	9	6	5	7	6	6	6	6	7	7	6	3	4	7	6	M	
	Lung Scan	4	6	7	5	3	5	6	4	3	6	4	6	7	6	3	4	7	5	M	
258. Routine surveillance (1-2 years) in a patient with dilated neo-aortic root with increasing Z scores, or neo-aortic regurgitation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
	TEE	3	3	1	3	3	2	9	3	3	3	3	1	3	3	9	4	5	3	R	
	CMR	6	8	7	9	8	8	7	8	9	8	8	8	7	8	8	7	9	8	A	
	CCT	6	7	7	9	8	7	7	7	9	7	7	8	7	8	7	7	7	7	A	
259. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
	CMR	8	5	4	5	8	4	3	7	4	5	3	5	7	7	6	6	9	5	M	
	CCT	7	5	4	5	7	4	3	7	4	4	3	5	7	7	5	4	7	5	M	
	Stress Imaging	7	4	4	9	6	4	3	6	3	3	3	5	7	7	4	4	7	4	M	
Post-operative: Rastelli	260. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	261. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	7	5	5	9	5	5	6	5	6	6	6	5	4	6	6	5	5	5	M
		CMR	7	6	7	9	8	7	7	7	9	6	6	6	7	7	6	7	8	7	A
		CCT	7	6	7	9	7	7	7	7	9	6	6	6	7	7	6	7	7	7	A
		Stress Imaging	6	6	5	9	5	5	7	5	3	6	4	5	7	7	6	7	6	6	M
		Lung Scan	7	6	5	9	4	5	6	5	3	7	5	5	7	7	7	7	6	6	M
	262. Routine surveillance (3-6 months) within the first year following repair	TTE	9	8	9	9	9	9	9	9	3	9	9	9	9	9	9	8	9	A	
	263. Routine surveillance (6 months) after the first year following repair in an asymptomatic patient with no or mild sequelae	TTE	9	6	6	9	9	5	9	7	9	6	9	9	9	7	6	9	8	9	A
		CMR	6	3	3	3	5	1	4	3	3	3	2	2	3	3	3	5	7	3	R
		CCT	5	3	3	3	3	1	4	3	3	3	2	2	3	3	3	4	6	3	R
	264. Routine surveillance (1-2 years) in an asymptomatic patient with no or mild sequelae	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A	
		CMR	3	4	3	5	6	5	4	5	3	5	3	4	5	5	4	5	7	5	M
CCT		3	4	3	5	5	5	4	5	3	5	3	4	5	5	4	4	7	4	M	
265. Routine surveillance (3-5 years) in an asymptomatic patient	CMR	4	6	7	9	7	7	7	6	6	5	7	9	9	7	6	6	8	7	A	
	CCT	4	7	9	7	7	7	7	6	7	7	8	7	7	8	5	4	6	7	A	

266. Routine surveillance (3-12 months) in a patient with valvular dysfunction, LVOT obstruction, presence of a RV to PA conduit, branch pulmonary artery stenosis, or arrhythmia	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	5	5	5	9	6	6	4	5	9	7	4	5	4	5	5	6	8	5	M		
	CCT	6	5	5	9	4	4	4	5	9	4	4	5	4	5	4	5	7	5	M		
	Stress Imaging	3	3	3	9	2	3	4	3	6	3	3	3	4	5	3	5	6	3	R		
	Lung Scan	3	4	3	9	3	3	4	3	6	3	4	4	4	3	3	4	5	4	M		
267. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	7	5	5	5	7	5	3	7	9	5	3	6	4	3	6	7	6	5	M		
	CCT	7	5	5	5	6	5	3	7	9	4	3	6	4	5	5	5	5	5	M		
	Stress Imaging	6	4	5	9	7	5	3	5	3	3	3	5	4	5	4	4	5	5	M		
Post-operative: Atrial Switch Operation 268. Evaluation due to concerning signs or symptoms and/or change in clinical status	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TTE + Contrast	9	6	7	9	4	7	6	8	6	6	5	6	6	6	6	8	6	6	M		
	TEE	6	6	7	9	6	7	7	7	6	6	7	6	6	6	6	8	6	6	M		
	CMR	7	7	7	9	7	8	7	8	6	7	7	7	6	7	7	8	9	7	A		
	CCT	7	7	7	9	6	7	7	7	6	7	7	7	6	7	7	8	7	7	A		
	Stress Imaging	6	5	7	9	4	4	7	3	6	5	6	5	6	5	6	8	6	6	M		
269. Routine surveillance (6 months) in an asymptomatic patient with no or mild sequelae	TTE	6	3	4	3	3	2	1	3	3	2	3	2	4	3	1	3	6	3	R		
	TTE + Contrast	3	3	3	5	3	3	3	3	3	3	3	2	3	3	3	5	5	3	R		
	CMR	5	3	3	1	3	2	3	3	3	3	1	2	3	3	3	3	6	3	R		
	CCT	5	3	3	1	3	2	3	3	3	3	1	2	3	3	3	3	4	3	R		
270. Routine surveillance (1-2 years) in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
	TTE + Contrast	3	3	3	5	3	3	3	3	3	3	3	5	3	3	3	5	5	3	R		
	CMR	4	3	4	3	3	2	1	3	3	2	4	2	3	3	5	9	5	3	R		
	CCT	3	3	3	2	3	2	1	3	3	2	4	2	3	3	5	7	5	3	R		
271. Routine surveillance (3-5 years) in an asymptomatic patient	TTE + Contrast	3	3	5	5	3	3	4	3	3	3	3	9	3	5	3	5	7	3	R		
	CMR	6	7	7	9	7	7	7	7	7	7	8	9	4	7	6	7	8	7	A		
	CCT	5	7	7	9	5	7	7	7	7	7	7	9	4	7	5	4	6	7	A		
272. Routine surveillance (3-12 months) in a patient with moderate systemic AV valve regurgitation, systemic RV dysfunction, LVOT obstruction, or arrhythmia	TTE	9	9	7	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	6	5	3	9	4	5	3	5	6	5	6	6	3	5	5	7	5	5	M		
	CMR	8	7	4	9	8	7	4	7	4	7	6	6	5	7	6	7	8	7	A		
	CCT	7	7	4	9	7	7	4	7	4	7	5	6	5	7	5	5	7	7	A		
	Stress Imaging	6	5	3	9	5	6	4	5	3	5	4	5	5	5	4	7	6	5	M		

282. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE + Contrast	9	5	5	5	5	4	6	5	6	4	6	5	5	5	5	6	6	5	M
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TTE + Contrast	7	5	5	9	5	5	6	5	9	5	6	5	5	5	5	7	6	5	M
	TEE	4	5	5	9	5	5	6	5	9	5	5	5	5	5	5	7	6	5	M
	CMR	4	7	7	9	8	7	7	7	9	7	7	6	7	7	7	7	7	7	A
	CCT	4	7	7	9	7	7	7	7	9	6	7	6	7	7	6	7	6	7	A
	Stress Imaging	4	6	6	9	6	6	6	6	4	6	4	5	6	6	6	7	6	6	M
283. Routine surveillance (3-6 months) within a year following repair in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	8	9	1	9	9	9	9	9	9	9	A	
284. Routine surveillance (1-2 years) after the first year following repair in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A
	CMR	7	5	5	9	5	5	4	5	4	5	6	7	5	5	5	7	6	5	M
	CCT	6	5	5	7	5	5	4	5	4	5	6	7	5	5	5	5	6	5	M
	Stress Imaging	6	4	5	9	5	4	6	4	3	4	4	6	5	5	4	5	5	5	M
285. Routine surveillance (6-12 months) in a patient with valvular or ventricular dysfunction, right or left ventricular outflow tract obstruction, or presence of a RV-to-PA conduit	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	5	3	5	9	7	2	3	3	6	3	3	3	5	3	3	5	5	3	R
	CMR	3	7	8	7	7	7	9	7	7	7	5	7	7	8	5	6	6	7	A
	CCT	3	7	7	7	7	7	9	6	7	7	5	7	7	8	5	5	6	7	A
	Stress Imaging	5	5	3	5	5	2	3	5	4	5	5	3	5	5	4	5	5	5	M
286. Routine surveillance (3-5 years) in an asymptomatic patient	TEE	5	5	5	9	7	5	3	5	5	4	5	5	5	5	5	5	5	5	M
	CMR	7	7	7	9	8	7	7	7	9	7	7	7	7	7	7	7	9	7	A
	CCT	7	7	7	9	8	7	7	7	9	7	7	7	7	7	6	7	7	7	A
	Stress Imaging	5	5	5	9	7	5	7	5	9	5	6	5	7	5	5	6	5	5	M
287. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	7	6	5	9	8	6	3	6	6	6	5	6	5	7	6	8	7	6	M
	CCT	7	6	5	9	8	6	3	6	6	6	5	6	5	7	5	5	6	6	M
Post-operative: Physiologic Repair with VSD closure and/or LV to PA conduit	288. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	289. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		TEE	7	6	6	9	8	6	3	6	6	6	5	7	5	6	7	6	6	M
		CMR	7	7	7	9	8	7	6	7	9	7	7	6	7	7	7	8	7	A

290. Routine surveillance (3-6 months) within a year following repair in an asymptomatic patient with no or mild sequelae	CCT	7	7	7	9	8	7	6	7	9	7	7	6	7	7	6	7	7	7	A
	Stress Imaging	6	6	6	9	6	6	6	6	6	5	4	5	7	5	6	7	6	6	M
	TTE	9	9	9	9	9	9	9	8	9	3	9	9	9	7	9	9	6	9	A
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
	TEE	4	5	3	5	4	5	3	5	4	5	3	3	1	5	5	5	6	5	M
	CMR	5	3	4	3	3	3	3	5	3	2	3	2	3	8	9	9	5	3	R
	CCT	5	3	3	2	3	3	3	5	3	2	3	2	3	7	9	6	5	3	R
	Stress Imaging	4	2	3	2	3	2	3	3	3	2	3	2	3	7	9	6	4	3	R
	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	4	5	3	9	4	5	3	5	4	5	3	3	7	5	5	5	6	5	M
CMR	4	8	7	9	8	8	7	8	7	7	7	7	7	7	8	7	7	7	A	
CCT	4	7	7	9	7	7	7	7	7	4	7	7	7	7	7	7	5	7	A	
Stress Imaging	4	5	6	9	5	5	7	5	6	4	5	4	7	5	5	7	6	5	M	
292. Routine surveillance (3-5 years) in an asymptomatic patient with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	4	5	3	9	4	5	3	5	4	5	3	3	7	5	5	5	6	5	M
	CMR	4	8	7	9	8	8	7	8	7	7	7	7	7	7	8	7	7	7	A
	CCT	4	7	7	9	7	7	7	7	7	4	7	7	7	7	7	7	5	7	A
	Stress Imaging	4	5	6	9	5	5	7	5	6	4	5	4	7	5	5	7	6	5	M
293. Routine surveillance (3-12 months) in a patient with ≥ moderate systemic AV valve regurgitation, systemic RV dysfunction, and/or LV-to-PA conduit dysfunction	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	TEE	4	5	6	9	6	5	3	5	6	5	4	4	5	5	5	6	6	5	M
	CMR	7	7	6	9	7	7	4	7	9	7	7	5	5	7	7	7	7	7	A
	CCT	6	7	7	7	8	7	9	6	7	7	6	7	7	7	5	6	6	7	A
	Stress Imaging	6	5	5	9	5	5	4	5	6	4	5	4	5	5	5	5	6	5	M
294. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
	CMR	7	5	5	9	8	6	3	7	6	5	7	6	5	7	6	7	6	6	M
	CCT	7	4	5	9	7	6	3	7	6	4	6	6	5	7	5	6	5	6	M

Table 18: Truncus Arteriosus (TA)

Unrepaired	295. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	7	7	7	9	7	6	7	7	3	7	7	5	5	7	7	7	8	7	A
		CCT	7	7	7	9	6	6	7	7	3	7	7	5	5	7	7	7	7	7	A
	296. Evaluation prior to planned repair	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
		CMR	7	6	7	9	7	7	7	7	6	7	7	9	7	7	7	8	7	A	
		CCT	7	5	7	9	7	7	7	7	5	7	7	9	7	7	7	7	7	A	
Post-operative	297. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
	298. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	A		

299. Routine surveillance (1-3 months) within the first year following repair in an asymptomatic patient	TEE	5	5	6	9	6	4	6	5	6	5	5	5	6	5	5	7	6	5	M
	CMR	8	7	7	9	8	7	6	7	6	7	8	7	6	7	7	7	7	7	A
	CCT	7	7	7	9	7	7	6	7	6	7	8	7	6	7	7	7	6	7	A
	Stress Imaging	5	5	5	9	7	5	6	5	6	5	5	5	6	5	5	7	6	5	M
	Lung Scan	5	5	5	9	7	5	6	5	6	5	5	5	6	5	5	7	5	5	M
TTE	9	9	9	9	9	9	9	6	9	2	9	9	9	7	9	9	9	9	A	
300. Routine surveillance (6-12 months) after the first year following repair in an asymptomatic child or adult with no or mild sequelae	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
	TEE	4	2	3	2	1	1	3	3	2	3	3	2	3	2	9	3	5	3	R
301. Routine surveillance (3-5 years) in an asymptomatic child or adult with no or mild sequelae	TEE	4	2	3	3	4	4	6	4	4	5	4	2	5	3	5	3	5	4	M
	CMR	6	6	6	5	6	6	6	6	3	6	7	7	6	5	6	7	7	6	M
	CCT	5	5	6	5	5	5	6	5	3	5	7	7	6	5	5	5	6	5	M
	Stress Imaging	5	5	5	9	5	5	6	5	6	5	4	5	6	5	5	4	5	5	M
302. Routine surveillance (3-6 months) in an asymptomatic child or adult with ≥ moderate truncal stenosis and/or regurgitation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
	TEE	5	5	4	5	4	3	3	5	4	6	2	3	1	5	5	4	4	4	M
	CMR	5	5	5	5	6	3	6	6	6	6	3	3	1	5	5	5	7	5	M
	CCT	5	4	5	5	4	3	6	5	6	6	3	3	1	5	4	4	6	5	M
	Stress Imaging	3	5	5	5	2	3	6	4	6	1	3	3	1	5	5	4	5	4	M
303. Routine surveillance (1-2 years) in an asymptomatic child or adult with ≥ moderate truncal stenosis and/or regurgitation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	TEE	5	6	4	9	4	6	3	5	4	6	5	6	5	7	6	6	6	6	M
	CMR	5	7	6	9	7	7	7	6	9	5	7	7	6	7	6	7	8	7	A
	CCT	4	7	5	7	9	6	9	6	7	7	7	7	7	6	6	6	6	7	A
	Stress Imaging	4	6	4	9	3	6	7	4	6	5	4	4	6	7	3	5	6	5	M
304. Routine surveillance (3-12 months) in a patient with known residual VSD, presence of a RV-to-PA conduit, or branch PA obstruction	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A
	TEE	6	4	4	9	6	4	4	4	6	4	4	3	6	5	4	6	4	4	M
	CMR	7	6	6	9	7	6	4	6	7	6	6	5	6	5	6	7	6	6	M
	CCT	7	6	6	9	5	6	4	6	9	6	6	5	6	5	6	6	5	6	M
	Lung Scan	7	5	5	9	7	5	4	4	9	5	5	5	6	5	5	4	4	5	M
305. Routine surveillance (3-12 months) in a patient with heart failure symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
	CMR	7	5	4	9	7	5	3	7	9	7	6	6	4	5	7	7	6	6	M
	CCT	7	5	4	9	5	5	9	6	6	4	6	6	4	5	5	5	5	5	M

Table 19: Single Ventricle Heart Disease

Unrepaired	306. Routine surveillance (1-4 week(s)) in a patient with balanced systemic and pulmonary circulation not requiring neonatal surgery	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	7	9	A			
		307. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	8	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
			TEE	3	3	3	5	4	2	3	3	6	3	4	4	6	3	3	7	4			3	R	
			CMR	7	6	6	9	5	6	5	6	9	6	7	6	6	5	6	7	7			6	M	
			CCT	6	5	6	9	4	6	5	5	9	5	7	6	6	5	5	7	6			6	M	
			Lung Scan	3	1	4	9	2	4	5	3	9	3	6	4	1	5	2	5	4			4	M	
		308. Evaluation prior to planned surgical palliation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
			TEE	4	4	3	2	3	1	5	5	3	3	3	1	3	3	9	6	4			3	R	
			CMR	7	7	7	9	7	7	6	7	9	7	8	7	6	7	7	7	7			7	A	
			CCT	6	6	7	9	7	7	6	7	9	7	7	7	6	7	6	7	6			7	A	
			Lung Scan	3	1	4	9	3	5	6	3	3	4	5	4	1	5	2	7	4			4	M	
		Post-procedural: Surgery and/or Catheter-based (Stage 1 Palliation)	309. Routine post-procedural evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
				CMR	3	3	3	3	4	2	3	3	3	3	3	2	1	3	3	5	5			3	R
				CCT	3	2	3	3	5	2	3	3	3	3	3	2	1	3	3	5	4			3	R
310. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE		9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
	TEE		7	4	4	5	7	4	4	4	6	4	4	4	6	4	2	5	6			4	M		
	CMR		8	7	7	9	7	7	6	8	6	7	8	6	6	7	6	7	7			7	A		
	CCT		7	7	7	9	7	7	6	7	6	7	7	6	6	7	5	7	6			7	A		
	Lung Scan		5	3	5	9	7	5	6	3	6	5	4	6	1	5	2	5	6			5	M		
311. Routine surveillance (1-4 weeks) in an asymptomatic infant	TTE		9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
	312. Evaluation prior to planned stage 2 palliation		TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
			TEE	4	4	4	5	6	2	3	4	7	4	4	4	6	3	4	5	5			4	M	
			CMR	7	8	6	9	7	8	5	6	9	1	8	8	6	8	8	7	7			7	A	
			CCT	7	8	5	9	5	8	5	5	9	1	8	8	6	8	7	7	6			7	A	
Lung Scan	6		3	4	9	3	5	5	2	6	4	4	4	1	5	3	5	5			4	M			
Post-operative: Stage 2 Palliation	313. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A			
		TEE	3	3	3	1	5	2	3	3	3	3	1	1	6	3	3	5	3			3	R		
		CMR	4	3	3	1	7	2	3	3	3	3	3	3	6	3	3	6	4			3	R		
		CCT	4	3	3	1	6	2	3	3	3	3	2	3	6	3	3	6	4			3	R		
	314. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A		
		TTE + Contrast	6	6	6	5	5	6	2	3	6	6	6	4	1	7	6	7	6			6	M		
		TEE	5	4	4	5	4	4	3	7	6	4	5	5	4	4	4	5	4			4	M		

		CMR	7	8	8	9	8	8	6	7	6	8	8	6	4	7	8	8	6	8	A
		CCT	7	8	8	9	8	8	6	7	6	7	8	6	4	7	7	8	5	7	A
		Lung Scan	6	3	3	9	3	3	6	2	6	3	5	3	1	3	3	7	4	3	R
	315. Routine surveillance (1-6 months) in an asymptomatic infant or child	TTE	9	9	9	9	9	9	9	9	9	3	9	9	9	9	9	9	7	9	A
	316. Routine surveillance (1-2 years) in an asymptomatic adult	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		CMR	7	7	6	9	7	7	4	7	6	5	4	6	4	7	6	7	7	7	A
		CCT	6	7	5	9	7	7	4	7	6	5	4	6	4	7	5	5	6	6	M
	317. Evaluation prior to planned stage 3 palliation	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TTE + Contrast	5	5	6	5	4	5	3	5	3	5	5	4	4	5	5	7	7	5	M
		TEE	4	4	6	1	5	4	3	4	6	4	4	5	4	4	4	6	7	4	M
		CMR	9	8	7	1	7	8	6	7	9	8	8	8	4	8	8	7	8	8	A
		CCT	8	8	7	1	6	8	6	7	9	8	8	8	4	8	7	7	7	7	A
		Lung Scan	3	2	2	1	6	2	6	2	9	2	3	2	1	3	2	5	7	2	R
Post-operative: Stage 3 Palliation	318. Routine post-operative evaluation (within 30 days)	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TTE + Contrast	3	3	3	5	3	2	1	3	6	3	2	1	4	3	3	7	6	3	R
		TEE	3	3	3	9	3	2	3	6	6	3	2	1	4	3	3	6	4	3	R
		CMR	3	3	3	9	3	2	3	7	7	3	3	2	4	3	3	7	4	3	R
		CCT	3	3	3	9	4	2	3	7	7	3	3	2	4	3	3	7	4	3	R
	319. Evaluation due to change in clinical status and/or new concerning signs or symptoms	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TTE + Contrast	8	6	8	9	8	6	6	4	6	6	6	5	4	7	5	7	9	6	M
		TEE	5	7	6	9	7	6	3	7	6	7	6	5	4	7	7	7	9	7	A
		CMR	7	8	7	9	7	8	6	8	6	8	8	7	4	7	7	7	9	7	A
		CCT	7	8	7	9	8	8	6	8	6	8	8	7	4	7	7	7	9	7	A
		Stress Imaging	3	6	5	9	4	6	4	6	6	6	4	4	4	5	4	7	9	5	M
	320. Routine surveillance (3-6 months) within a year following stage 3 palliation in an asymptomatic patient	TTE	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	A
	321. Routine surveillance (6-12 months) after the first year following stage 3 palliation in an asymptomatic patient	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	9	A
		TEE	3	3	3	5	3	2	3	3	6	3	2	2	3	3	3	5	4	3	R
		CMR	5	7	6	3	3	3	3	3	3	3	1	3	3	6	5	6	5	3	R
		CCT	4	7	3	3	3	3	3	3	3	3	1	3	3	6	5	5	5	3	R
		Stress Imaging	3	1	3	5	2	3	3	2	3	1	1	2	4	3	3	5	4	3	R
	322. Routine surveillance (3-5 years) in an asymptomatic patient	TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
		TEE	3	5	3	9	5	5	3	5	6	5	3	4	3	5	5	6	4	5	M
		CMR	6	8	8	9	8	8	8	8	9	8	8	7	4	7	7	7	8	8	A
		CCT	6	7	8	9	6	7	8	7	9	7	7	7	4	7	6	7	7	7	A
		Stress Imaging	4	5	8	9	3	5	7	5	9	5	4	3	4	5	4	7	5	5	M

323. Routine surveillance (3-12 months) in a patient with valvular or ventricular dysfunction, arrhythmias, or other cardiac complications

TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A
CMR	8	5	6	9	7	5	4	5	6	5	8	6	4	7	7	7	5	6	M	
CCT	8	5	6	9	6	5	4	5	6	5	8	6	4	7	7	7	5	6	M	
Stress Imaging	5	4	6	9	3	4	4	4	6	4	4	4	4	5	6	7	3	4	M	
TTE	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	A	
CMR	9	5	6	5	7	5	3	6	9	5	6	6	4	7	7	7	9	6	M	
CCT	9	5	6	5	7	5	3	6	9	5	6	6	4	7	7	6	8	6	M	

324. Routine surveillance (3-12 months) in a patient with heart failure symptoms

Summary Analysis	
# of Appropriate scenarios	452
# of May Be Appropriate scenarios	407
# of Rarely Appropriate scenarios	176
Total # of scenarios	1035
% Appropriate scenarios	44%
% May Be Appropriate scenarios	39%
% Rarely Appropriate scenarios	17%